0001493152-19-006670.txt : 20190509 0001493152-19-006670.hdr.sgml : 20190509 20190509160622 ACCESSION NUMBER: 0001493152-19-006670 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 44 CONFORMED PERIOD OF REPORT: 20190331 FILED AS OF DATE: 20190509 DATE AS OF CHANGE: 20190509 FILER: COMPANY DATA: COMPANY CONFORMED NAME: LIXTE BIOTECHNOLOGY HOLDINGS, INC. CENTRAL INDEX KEY: 0001335105 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 202903526 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-51476 FILM NUMBER: 19810503 BUSINESS ADDRESS: STREET 1: 248 ROUTE 25A STREET 2: NO. 2 CITY: EAST SETAUKET STATE: NY ZIP: 11733 BUSINESS PHONE: 310 203 2902 MAIL ADDRESS: STREET 1: 248 ROUTE 25A STREET 2: NO. 2 CITY: EAST SETAUKET STATE: NY ZIP: 11733 FORMER COMPANY: FORMER CONFORMED NAME: SRKP 7 INC DATE OF NAME CHANGE: 20050803 10-Q 1 form10-q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2019

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number: 000-51476

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Delaware		20-2903526
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification Number)

248 Route 25A, No. 2

East Setauket, New York 11733

(Address of principal executive offices)

(631) 942-7959

(Registrant’s telephone number, including area code)

Not applicable

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company (as defined in Rule 12b-2 of the Exchange Act).

Large accelerated filer [ ]		Accelerated filer [ ]
Non-accelerated filer [ ]*		Smaller reporting company [X]
*(Do not check if a smaller reporting company)		Emerging growth company [ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes [ ] No [X]

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		LIXT		OTCQB

As of May 1, 2019, the Company had 67,045,814 shares of common stock, $0.0001 par value, issued and outstanding.

Documents incorporated by reference: None

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

AND SUBSIDIARY

TABLE OF CONTENTS

	Page Number

PART I - FINANCIAL INFORMATION

Item 1. Condensed Consolidated Financial Statements	4

Condensed Consolidated Balance Sheets – March 31, 2019 (Unaudited) and December 31, 2018	4

Condensed Consolidated Statements of Operations (Unaudited) – Three Months Ended March 31, 2019 and 2018	5

Condensed Consolidated Statements of Stockholders’ Equity (Unaudited) –Three Months Ended March 31, 2019	6

Condensed Consolidated Statements of Cash Flows (Unaudited) – Three Months Ended March 31, 2019 and 2018	7

Notes to Condensed Consolidated Financial Statements (Unaudited) – Three Months Ended March 31, 2019 and 2018	8

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	20

Item 3. Quantitative and Qualitative Disclosures About Market Risk	30

Item 4. Controls and Procedures	30

PART II - OTHER INFORMATION

Item 1. Legal Proceedings	31

Item 1A. Risk Factors	31

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	31

Item 3. Defaults Upon Senior Securities	31

Item 4. Mine Safety Disclosures	31

Item 5. Other Information	31

Item 6. Exhibits	31

SIGNATURES	32

Forward-Looking Statements

This Quarterly Report on Form 10-Q of Lixte Biotechnology Holdings, Inc. (the “Company”) contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These might include statements regarding the Company’s financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as “intend,” “anticipate,” “believe,” “estimate,” “potential(ly),” “continue,” “forecast,” “predict,” “plan,” “may,” “will,” “could,” “would,” “should,” “expect” or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. These forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected, anticipated or implied in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies or changes thereto, available cash, research and development results, competition from other similar businesses, and market and general economic factors. This discussion should be read in conjunction with the condensed consolidated financial statements and notes thereto included in Item 1 of this Quarterly Report on Form 10-Q and the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018, including the section entitled “Item 1A. Risk Factors”. The Company does not intend to update or revise any forward-looking statements to reflect new information, future events or otherwise.

PART I - FINANCIAL INFORMATION

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

AND SUBSIDIARY

CONDENSED CONSOLIDATED BALANCE SHEETS

	March 31, 2019			December 31, 2018
		(Unaudited)

ASSETS
Current assets:
Cash and cash equivalents	$	3,893,604		$	4,273,012
Accrued intertest receivable		4,161			—
Prepaid expenses and other current assets		57,070			61,433
Total current assets		3,954,835			4,334,445
Prepaid expense, less current portion		—			2,293
Total assets	$	3,954,835		$	4,336,738

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable and accrued expenses	$	210,673		$	195,211
Research and development contract liabilities		34,139			15,704
Total current liabilities		244,812			210,915

Commitments and contingencies

Stockholders’ equity:
Preferred Stock, $0.0001 par value; authorized – 10,000,000 shares; issued and outstanding – 350,000 shares of Series A Convertible Preferred Stock, $10.00 per share stated value, $50.00 per share cash redemption value; aggregate cash redemption value – $17,500,000; liquidation preference based on assumed conversion into common shares – 4,375,000 shares		3,500,000			3,500,000
Common stock, $0.0001 par value; authorized – 100,000,000 shares; issued and outstanding – 67,045,814 shares		6,704			6,704
Additional paid-in capital		25,280,598			25,267,662
Accumulated deficit		(25,077,279	)		(24,648,543	)
Total stockholders’ equity		3,710,023			4,125,823
Total liabilities and stockholders’ equity	$	3,954,835		$	4,336,738

See accompanying notes to condensed consolidated financial statements.

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

	Three Months Ended March 31,
	2019			2018

Revenues	$	—		$	—

Costs and expenses:
General and administrative costs, including $12,000 and $12,000 to related parties for the three months ended March 31, 2019 and 2018, respectively		390,428			354,070
Research and development costs, including $33,897 and $0 to Theradex for the three months ended March 31, 2019 and 2018, respectively		48,314			25,689
Total costs and expenses		438,742			379,759
Loss from operations		(438,742	)		(379,759	)
Interest income		10,006			599
Net loss	$	(428,736	)	$	(379,160	)

Net loss per common share – basic and diluted	$	(0.01	)	$	(0.01	)

Weighted average common shares outstanding – basic and diluted		67,045,814			58,025,814

See accompanying notes to condensed consolidated financial statements.

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(Unaudited)

Three Months Ended March 31, 2019 and 2018

	Series A
	Convertible
	Preferred Stock				Common Stock				Additional					Total
							Par		Paid-in		Accumulated			Stockholders’
	Shares		Amount		Shares		Value		Capital		Deficit			Equity

Balance, December 31, 2018		350,000	$	3,500,000		67,045,814	$	6,704	$	25,267,662	$	(24,648,543	)	$	4,125,823
Stock-based compensation expense		—		—		—		—		12,936		—			12,936
Net loss		—		—		—		—		—		(428,736	)		(428,736	)
Balance, March 31, 2019		350,000	$	3,500,000		67,045,814	$	6,704	$	25,280,598	$	(25,077,279	)	$	3,710,023

Balance, December 31, 2017		350,000	$	3,500,000		58,025,814	$	5,802	$	20,004,654	$	(22,515,415	)	$	995,041
Net loss		—		—		—		—		—		(379,160	)		(379,160	)
Balance, March 31, 2018		350,000	$	3,500,000		58,025,814	$	5,802	$	20,004,654	$	(22,894,575	)	$	615,881

See accompanying notes to condensed consolidated financial statements.

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

	Three Months Ended March 31,
	2019			2018

Cash flows from operating activities:
Net loss	$	(428,736	)	$	(379,160	)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense included in -
General and administrative costs		12,936			—
Research and development costs		—			—
Changes in operating assets and liabilities:
(Increase) decrease in -
Accrued interest receivable		(4,161	)		—
Prepaid expenses and other current assets		6,656			15,796
Increase (decrease) in -
Accounts payable and accrued expenses		15,462			(123,546	)
Research and development contract liabilities		18,435			(10,800	)
Net cash used in operating activities		(379,408	)		(497,710	)

Cash and cash equivalents:
Net decrease		(379,408	)		(497,710	)
Balance at beginning of period		4,273,012			1,305,748
Balance at end of period	$	3,893,604		$	808,038

Supplemental disclosures of cash flow information:
Cash paid for -
Interest	$	—		$	—
Income taxes	$	—		$	—

See accompanying notes to condensed consolidated financial statements.

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

AND SUBSIDIARY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Three Months Ended March 31, 2019 and 2018

1. Organization and Basis of Presentation

The condensed consolidated financial statements of Lixte Biotechnology Holdings, Inc., a Delaware corporation (“Holdings”), including its wholly-owned Delaware subsidiary, Lixte Biotechnology, Inc. (“Lixte”) (collectively, the “Company”), at March 31, 2019, and for the three months ended March 31, 2019 and 2018, are unaudited. In the opinion of management of the Company, all adjustments, including normal recurring accruals, have been made that are necessary to present fairly the financial position of the Company as of March 31, 2019, and the results of its operations for the three months ended March 31, 2019 and 2018, and its cash flows for the three months ended March 31, 2019 and 2018. Operating results for the interim periods presented are not necessarily indicative of the results to be expected for a full fiscal year. The consolidated balance sheet at December 31, 2018 has been derived from the Company’s audited consolidated financial statements at such date.

The condensed consolidated financial statements and related notes have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been omitted pursuant to such rules and regulations. These condensed consolidated financial statements should be read in conjunction with the financial statements and other information included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018, as filed with the SEC.

2. Business

The Company is a drug discovery company that uses biomarker technology to identify enzyme targets associated with serious common diseases and then designs novel compounds to attack those targets. The Company’s product pipeline encompasses two major categories of compounds at various stages of pre-clinical and clinical development that the Company believes have broad therapeutic potential not only for cancer but also for other debilitating and life-threatening diseases.

The Company’s activities are subject to significant risks and uncertainties, including the need for additional capital, as described below. The Company has not yet commenced any revenue-generating operations, does not have positive cash flows from operations, and is dependent on periodic infusions of equity capital to fund its operating requirements.

The Company’s common stock is traded on the OTCQB operated by the OTC Markets under the symbol “LIXT”.

Going Concern

The Company’s consolidated financial statements have been presented on the basis that it is a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has not generated any revenues from operations to date and does not expect to do so in the foreseeable future. Furthermore, the Company has experienced recurring operating losses and negative operating cash flows since inception and has financed its working capital requirements during this period primarily through the recurring sale of its equity securities and the exercise of outstanding common stock options and purchase warrants.

As a result, management has concluded that there is substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the consolidated financial statements are being issued. In addition, the Company’s independent registered public accounting firm, in their report on the Company’s consolidated financial statements for the year ended December 31, 2018, has also expressed substantial doubt about the Company’s ability to continue as a going concern.

The Company’s ability to continue as a going concern is dependent upon its ability to raise additional equity capital to fund its research and development activities and to ultimately achieve sustainable operating revenues and profits. The Company’s consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.

Because the Company is currently engaged in clinical research at a relatively early stage, it will likely take a significant amount of time to develop any product or intellectual property capable of generating sustainable revenues. Accordingly, the Company’s business is unlikely to generate any sustainable operating revenues in the next several years and may never do so. In addition, to the extent that the Company is able to generate revenues through licensing its technologies or through product sales, there can be no assurance that the Company will be able to achieve positive earnings and operating cash flows.

Effective November 30, 2018, the Company raised $4,500,000 through the sale to sixteen accredited investors of 9,000,000 units at a purchase price of $0.50 per unit. Each unit consisted of one share of common stock and one four-year warrant to purchase one share of common stock at an exercise price of $1.00 per share. Accordingly, a total of 9,000,000 shares of common stock and warrants to purchase 9,000,000 shares of common stock were issued by the Company. The warrants do not have any reset provisions.

At March 31, 2019, the Company had cash and cash equivalents of $3,893,604 available to fund its operations. The next step in the development of the Company’s lead anti-cancer clinical compound LB-100 is to evaluate its therapeutic benefit in Phase 1b/2 clinical trials. The initial clinical trial evaluating LB-100 in myelodysplastic syndrome (MDS) began during April 2019 and is expected to complete patient accrual over a period of two years, with final analysis and reporting expected within three years. The Company’s longer-term objective is to secure one or more strategic partnerships with pharmaceutical companies with major programs in cancer.

The amount and timing of future cash requirements will depend on the pace and design of the Company’s clinical trial program. As market conditions present uncertainty as to the Company’s ability to secure additional funds, there can be no assurances that the Company will be able to secure additional financing on acceptable terms, or at all, as and when necessary to continue to conduct operations. If cash resources are insufficient to satisfy the Company’s ongoing cash requirements, the Company would be required to scale back or discontinue its technology and product development programs and/or any clinical trials, or obtain funds, if available (although there can be no certainty), through strategic alliances that may require the Company to relinquish rights to certain of its compounds, or to discontinue its operations entirely.

3. Summary of Significant Accounting Policies

Principles of Consolidation

The accompanying condensed consolidated financial statements of the Company have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) and include the financial statements of Holdings and its wholly-owned subsidiary, Lixte. Intercompany balances and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable in relation to the financial statements taken as a whole under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Management regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available information, changes in facts and circumstances, historical experience and reasonable assumptions. After such evaluations, if deemed appropriate, those estimates are adjusted accordingly. Actual results could differ from those estimates. Significant estimates include those related to assumptions used in accruals for potential liabilities, valuing equity instruments issued for services, and the realization of deferred tax assets.

Cash and Cash Equivalents

Cash and cash equivalents include short-term federally insured certificates of deposit. The Company maintains its cash balances with financial institutions in federally-insured accounts. The Company may periodically have cash balances in banks in excess of FDIC insurance limits. The Company maintains its accounts with financial institutions with high credit ratings. The Company has not experienced any losses to date resulting from this practice.

Research and Development

Research and development costs consist primarily of fees paid to consultants and outside service providers, and other expenses relating to the acquisition, design, development and testing of the Company’s compounds and product candidates.

Research and development costs are charged to operations ratably over the life of the underlying contracts, unless the achievement of milestones, the completion of contracted work, or other information indicates that a different expensing schedule is more appropriate.

Obligations incurred with respect to mandatory scheduled payments under research agreements without milestone provisions are recognized ratably over the appropriate period, as specified in the agreement, and are recorded as liabilities in the Company’s consolidated balance sheet, with a corresponding charge to research and development costs in the Company’s consolidated statement of operations.

On January 10, 2010, the Company retained Theradex Systems, Inc. (“Theradex”) under a Master Agreement to provide technical and advisory services to the Company with respect to clinical trial matters involving the U.S. Food and Drug Administration (“FDA”). Theradex is an international contract research organization (“CRO”) that provides technical and advisory services with respect to clinical research and development of pharmaceutical compounds under the rules and regulations of the FDA. On September 21, 2012, the Company entered into a work order agreement with Theradex to manage and administer the Company’s Phase 1 clinical trial of LB-100. This Phase 1 clinical trial had been substantially completed at December 31, 2017.

On September 12, 2018, the Company finalized a work order agreement with Theradex to monitor a Phase 1b/2 clinical trial that was approved by the FDA in early November 2018 to evaluate the therapeutic benefit of LB-100 in MDS. This clinical trial began during April 2019 and is expected to complete patient accrual over a period of two years, with final analysis and reporting expected within three years. The clinical trial will be managed and conducted by the Moffitt Cancer Center and Research Institute Hospital Inc., Tampa, Florida, to evaluate the therapeutic benefit of the Company’s lead anti-cancer clinical compound LB-100 administered intravenously in patients with low or intermediate-1 risk myelodysplastic syndrome (MDS). This work order agreement became operational in August 2018 and is estimated to be completed by December 2021. Costs under this work order agreement are estimated to be approximately $954,000, with such payments expected to be divided approximately 94% to Theradex for services and approximately 6% for payments for pass-through costs. The costs of the upcoming Phase 1b/2 clinical trial to be paid to or through Theradex will be recorded and charged to operations based on the periodic documentation provided by the CRO. During the three months ended March 31, 2019, the Company paid Theradex $32,964 pursuant to this work order. As of March 31, 2019, total costs of $44,870 have been incurred pursuant to this work order agreement.

In addition to the costs associated with the previously described work order agreements with Theradex with respect to the Company’s clinical trials, the Company has also from time to time engaged Theradex to provide other technical and advisory services.

Payments made pursuant to research and development contracts are initially recorded as advances on research and development contract services in the Company’s consolidated balance sheet and then charged to research and development costs in the Company’s consolidated statement of operations as those contract services are performed. Expenses incurred under research and development contracts in excess of amounts advanced are recorded as research and development contract liabilities in the Company’s consolidated balance sheet, with a corresponding charge to research and development costs in the Company’s consolidated statement of operations. The Company reviews the status of its research and development contracts on a quarterly basis.

Patent and Licensing Costs

Due to the significant uncertainty associated with the successful development of one or more commercially viable products based on the Company’s research efforts and related patent applications, all patent-related legal and filing fees and licensing-related legal fees are charged to operations as incurred. Patent and licensing costs were $190,773 and $217,659 for the three months ended March 31, 2019 and 2018, respectively. Patent and licensing costs are included in general and administrative costs in the Company’s consolidated statements of operations.

Concentration of Risk

The Company periodically contracts with directors, including companies controlled by or associated with directors, to provide consulting services related to the Company’s research and development and clinical trial activities. Agreements for these services can be for a specific time period (typically one year) or for a specific project or task and can include both cash and non-cash compensation. The only such contracts that represent 10% or more of general and administrative or research and development costs are described below.

As discussed above at “Research and Development”, the Company had retained Theradex to provide technical and advisory services to the Company with respect to clinical trial matters involving the FDA, including monitoring a Phase 1b/2 clinical trial that was approved by the FDA in early November 2018 to evaluate the therapeutic benefit of LB-100 in MDS. This clinical trial began during April 2019 and is expected to complete patient accrual over a period of two years, with final analysis and reporting expected within three years.

Costs incurred pursuant to the agreements with Theradex are included in research and development costs in the Company’s consolidated statements of operations.

Income Taxes

The Company accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly, the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and the tax basis of assets and liabilities.

The Company has elected to deduct research and development costs on a current basis for federal income tax purposes. For federal tax purposes, start-up and organization costs were deferred until January 1, 2008 at which time the Company began to amortize such costs over a 180-month period.

The Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. In the event the Company was to determine that it would be able to realize its deferred tax assets in the future in excess of its recorded amount, an adjustment to the deferred tax assets would be credited to operations in the period such determination was made. Likewise, should the Company determine that it would not be able to realize all or part of its deferred tax assets in the future, an adjustment to the deferred tax assets would be charged to operations in the period such determination was made.

The Company is subject to U.S. federal income taxes and income taxes of various state tax jurisdictions. As the Company’s net operating losses have yet to be utilized, all previous tax years remain open to examination by Federal authorities and other jurisdictions in which the Company currently operates or has operated in the past. The Company had no unrecognized tax benefits as of March 31, 2019 and December 31, 2018 and does not anticipate any material amount of unrecognized tax benefits within the next 12 months.

The Company accounts for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by GAAP. The tax effects of a position are recognized only if it is “more-likely-than-not” to be sustained by the taxing authority as of the reporting date. If the tax position is not considered “more-likely-than-not” to be sustained, then no benefits of the position are recognized. As of March 31, 2019, the Company had not recorded any liability for uncertain tax positions. In subsequent periods, any interest and penalties related to uncertain tax positions will be recognized as a component of income tax expense.

Stock-Based Compensation

The Company periodically issues common stock and stock options to officers, directors, Scientific Advisory Committee members and consultants for services rendered. Options vest and expire according to terms established at the issuance date of each grant.

The Company accounts for stock-based payments to officers and directors by measuring the cost of services received in exchange for equity awards utilizing the grant date fair value of the awards, with the cost recognized as compensation expense on the straight-line basis in the Company’s financial statements over the vesting period of the awards. The Company accounts for stock-based payments to Scientific Advisory Committee members and consultants by determining the value of the stock compensation based upon the measurement date at either (a) the date at which a performance commitment is reached or (b) at the date at which the necessary performance to earn the equity instruments is complete.

Stock grants, which are generally time vested, are measured at the grant date fair value and charged to operations ratably over the vesting period.

Stock options granted to members of the Company’s Scientific Advisory Committee and to outside consultants are revalued each reporting period to determine the amount to be recorded as an expense in the respective period. As the stock options vest, they are valued on each vesting date and an adjustment is recorded for the difference between the value already recorded and the value on the date of vesting.

The fair value of common stock issued as stock-based compensation is determined by reference to the closing price of the Company’s common stock on the date of issuance. The fair value of stock options granted as stock-based compensation is determined utilizing the Black-Scholes option-pricing model, and is affected by several variables, the most significant of which are the life of the equity award, the exercise price of the stock option as compared to the fair market value of the common stock on the grant date, and the estimated volatility of the common stock over the term of the equity award. Estimated volatility is based on the historical volatility of the Company’s common stock. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant. The fair market value of common stock is determined by reference to the quoted market price of the Company’s common stock.

The Company recognizes the fair value of stock-based compensation awards in general and administrative costs and in research and development costs, as appropriate, in the Company’s consolidated statements of operations. The Company issues new shares of common stock to satisfy stock option exercises.

Earnings (Loss) Per Share

The Company’s computation of earnings (loss) per share (“EPS”) includes basic and diluted EPS. Basic EPS is measured as the income (loss) attributable to common stockholders divided by the weighted average common shares outstanding for the period. Diluted EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares (e.g., preferred shares, warrants and stock options) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS.

Loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the respective periods. Basic and diluted loss per common share is the same for all periods presented because all preferred shares, warrants and stock options outstanding are anti-dilutive.

At March 31, 2019 and 2018, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive.

	March 31,
	2019		2018

Series A Convertible Preferred Stock		4,375,000		4,375,000
Common stock warrants		9,000,000		—
Common stock options, including options issued in the form of warrants		7,750,000		7,470,000
Total		21,125,000		11,845,000

Fair Value of Financial Instruments

The authoritative guidance with respect to fair value established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels and requires that assets and liabilities carried at fair value be classified and disclosed in one of three categories, as presented below. Disclosure as to transfers in and out of Levels 1 and 2, and activity in Level 3 fair value measurements, is also required.

Level 1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities and exchange-based derivatives.

Level 2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities, non-exchange-based derivatives, mutual funds, and fair-value hedges.

Level 3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently-traded non-exchange-based derivatives and commingled investment funds and are measured using present value pricing models.

The Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company performs an analysis of the assets and liabilities at each reporting period end.

The carrying value of financial instruments (consisting of cash and cash equivalents, and accounts payable and accrued expenses) is considered to be representative of their respective fair values due to the short-term nature of those instruments.

Recent Accounting Pronouncements

In June 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update 2018-07, Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting (“ASU 2018-07”). ASU 2018-07 expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. ASU 2018-07 also clarifies that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Revenue from Contracts with Customers (Topic 606). ASU 2018-07 was effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company adopted the provisions of ASU 2018-07 in the quarter beginning January 1, 2019. The adoption of ASU 2018-07 did not have any impact on the Company’s financial statement presentation or disclosures.

Management does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the Company’s financial statement presentation or disclosures.

4. Stockholders’ Equity

Preferred Stock

The Company has authorized a total of 10,000,000 shares of preferred stock, par value $0.0001 per share. On March 17, 2015, the Company filed a Certificate of Designations, Preferences, Rights and Limitations (the “Certificate of Designations”) of its Series A Convertible Preferred Stock with the Delaware Secretary of State to amend the Company’s certificate of incorporation. The Company designated 175,000 shares as Series A Convertible Preferred Stock, which are non-voting and are not subject to increase without the written consent of a majority of the holders of the Series A Convertible Preferred Stock or as otherwise set forth in the Certificate of Designations. The holders of each tranche of 175,000 shares of the Series A Convertible Preferred Stock are entitled to receive a per share dividend equal to 1% of the annual net revenue of the Company divided by 175,000, until converted or redeemed.

Effective January 28, 2016, the Series A Convertible Preferred Stock Certificate of Designations was amended to increase the authorized shares of Series A Convertible Preferred Stock from 175,000 shares to 350,000 shares. Accordingly, as of March 31, 2019, 9,650,000 shares of preferred stock were undesignated and may be issued with such rights and powers as the Board of Directors may designate.

Each share of Series A Convertible Preferred Stock may be converted, at the option of the holder, into 12.5 shares of common stock (subject to customary anti-dilution provisions) and the Series A Convertible Preferred Stock is subject to mandatory conversion at the conversion rate in the event of a merger or sale transaction resulting in gross proceeds to the Company of at least $21,875,000. The Series A Convertible Preferred Stock has a liquidation preference based on its assumed conversion into shares of common stock. The Series A Convertible Preferred Stock does not have a cash liquidation preference.

If fully converted, the 350,000 outstanding shares of Series A Convertible Preferred Stock would convert into 4,375,000 shares of common stock at March 31, 2019. The Company has the right to redeem the Series A Convertible Preferred Stock up to the fifth anniversary of the respective closing dates at a price per share equal to $50.00. The Series A Convertible Preferred Stock has no right to cash, except for the payment of the aforementioned dividend based on the generation of revenues by the Company and does not have any registration rights.

Based on the attributes of the Series A Convertible Preferred Stock described above, the Company determined to account for the Series A Convertible Preferred Stock as a permanent component of stockholders’ equity.

Common Stock

The Company is authorized to issue up to 100,000,000 shares of common stock (par value $0.0001). As of March 31, 2019 and December 31, 2018, the Company had 67,045,814 shares of common stock issued and outstanding.

Common Stock Warrants

A summary of common stock warrant activity, including warrants to purchase common stock that were issued in conjunction with the Company’s private placements, during the three months ended March 31, 2019 is presented below.

	Number of Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (in Years)

Warrants outstanding at December 31, 2018		9,000,000	$	1.000
Issued		—		—
Exercised		—		—
Expired		—		—
Warrants outstanding at March 31, 2019		9,000,000	$	1.000		3.67

At March 31, 2019, all outstanding warrants are exercisable at $1.000 per common share.

Based on a fair market value of $0.90 per share on March 31, 2019, there were no exercisable but unexercised in-the-money common stock warrants on that date. Accordingly, there was no intrinsic value attributed to exercisable but unexercised common stock warrants at March 31, 2019.

Information with respect to the issuance of common stock in connection with various stock-based compensation arrangements is provided at Note 6.

5. Related Party Transactions

The Company’s Chairman and major stockholder, Dr. John Kovach, was paid a salary of $15,000 for the three months ended March 31, 2019 and 2018, which amounts are included in general and administrative costs in the Company’s consolidated statements of operations. Beginning in late February 2017, Dr. Kovach began devoting 100% of his time to the Company’s business activities.

The Company’s principal office facilities are being provided without charge by Dr. Kovach. Such costs were not material to the Company’s consolidated financial statements and, accordingly, have not been reflected therein.

On September 12, 2007, the Company entered into a consulting agreement with Gil Schwartzberg for Mr. Schwartzberg to provide financial advisory and consulting services to the Company with respect to financing matters, capital structure and strategic development, and to assist management in communications with investors and shareholders. Mr. Schwartzberg is currently a significant stockholder of the Company and continues to be a consultant to the Company. Consideration under this consulting agreement, including subsequent extensions, has been paid exclusively in the form of stock options. On January 28, 2014, the Company entered into a second amendment to its consulting agreement with Mr. Schwartzberg to extend it to January 28, 2019. In conjunction with such amendment, the Company granted Mr. Schwartzberg stock options to purchase an additional 4,000,000 shares of common stock, exercisable at $0.50 per share for a period of the earlier of five years from the grant date or the termination of the consulting agreement, with one-half of the stock options (2,000,000 shares) vested immediately and one-half of the stock options (2,000,000 shares) vested on January 28, 2015. Stock-based compensation expense with respect to the grant of the stock options to purchase the 4,000,000 shares of common stock was previously charged to general and administrative costs in the consolidated statement of operations over the vesting period. On August 2, 2018, with the approval of the Board of Directors, the Company entered into a third amendment to its consulting agreement with Mr. Schwartzberg to extend it to January 28, 2024. In conjunction with such amendment, the Company extended the expiration date of the fully-vested stock options for 4,000,000 shares of common stock previously granted to Mr. Schwartzberg, from January 28, 2019 to January 28, 2024. The fair value of the extension of these vested stock options, as calculated pursuant to the Black-Scholes option-pricing model, was measured for accounting purposes as the difference in the fair value of the stock options immediately before and immediately after the extension date, and was charged to general and administrative costs in the consolidated statement of operations on August 2, 2018.

Legal and consulting fees charged to operations for services rendered by the Eric Forman Law Office were $12,000 for the three months ended March 31, 2019 and 2018, respectively. Eric J. Forman is the son-in-law of Gil Schwartzberg, a significant stockholder of and consultant to the Company, and is the son of Dr. Stephen J. Forman, who was elected to the Company’s Board of Directors on May 13, 2016. Julie Forman, the wife of Eric Forman and the daughter of Gil Schwartzberg, is Vice President of Morgan Stanley Wealth Management, where the Company maintains a banking relationship.

Stock-based compensation arrangements involving members of the Company’s Board of Directors and affiliates are described at Note 6. Total stock-based compensation expense relating to directors, officers, affiliates and related parties was $12,936 and $0 for the three months ended March 31, 2019 and 2018, respectively.

6. Stock-Based Compensation

The Company issues common stock and stock options as incentive compensation to directors and as compensation for the services of independent contractors and consultants of the Company.

On June 20, 2007, the Board of Directors of the Company approved the 2007 Stock Compensation Plan (the “2007 Plan”), which provides for the granting of awards, consisting of stock options, stock appreciation rights, performance shares, or restricted shares of common stock, to employees and independent contractors, for up to 2,500,000 shares of the Company’s common stock, under terms and conditions as determined by the Company’s Board of Directors. The 2007 Plan terminated on June 19, 2017. As of March 31, 2019, unexpired stock options for 1,250,000 shares were issued and outstanding under the 2007 Plan.

The fair value of each stock option awarded is calculated on the date of grant and subsequent measurement dates using the Black-Scholes option-pricing model. The expected dividend yield assumption is based on the Company’s expectation of dividend payouts. The expected volatilities are based on historical volatility of the Company’s stock. The risk-free interest rate is based on the U.S. treasury yield curve in effect as of the grant date. The expected life of the stock options is the average of the vesting term and the full contractual term of the stock options.

There were no stock options requiring an assessment of value during the three months ended March 31, 2019 and 2018.

Effective August 4, 2018, in conjunction with their appointments as directors of the Company, the Company granted to Dr. Winson Sze Chun Ho and Dr. Yun Yen stock options for each person to purchase an aggregate of 200,000 shares of the Company’s common stock, exercisable for a period of five years from the vesting date at $0.28 per share, which was the approximate fair market value of the Company’s common stock on such date. One-half of such stock options (100,000 shares each) vested on August 4, 2018 and the remaining one-half of such stock options (100,000 shares each) will vest on August 4, 2019. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $104,920 ($0.2623 per share), of which $52,460 was attributable to the stock options fully-vested on August 4, 2018 and was therefore was charged to operations on that date. The remaining unvested portion of the fair value of the stock options will be charged to operations ratably from August 4, 2018 through August 4, 2019. During the three months ended March 31, 2019, the Company recorded a charge to operations of $12,936 with respect to these stock options.

Total stock-based compensation expense was $12,936 and $0 for the three months ended March 31, 2019 and 2018, respectively.

A summary of stock option activity, including options issued in the form of warrants, during the three months ended March 31, 2019 is presented below.

	Number of Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (in Years)

Stock options outstanding at December 31, 2018		7,750,000	$	0.583
Granted		—		—
Exercised		—		—
Expired		—		—
Stock options outstanding at March 31, 2019		7,750,000	$	0.538		3.43

Stock options exercisable at March 31, 2019		7,550,000	$	0.545		3.41

Total deferred compensation expense for the outstanding value of unvested stock options was approximately $18,000 at March 31, 2019, which will be recognized subsequent to March 31, 2018 over a weighted-average period of approximately four months.

The exercise prices of common stock options outstanding and exercisable, including options issued in the form of warrants, are as follows at March 31, 2019:

Exercise Prices		Options Outstanding (Shares)		Options Exercisable (Shares)

$	0.120		450,000		450,000
$	0.150		300,000		300,000
$	0.160		200,000		200,000
$	0.200		500,000		500,000
$	0.250		500,000		500,000
$	0.280		400,000		200,000
$	0.500		4,400,000		4,400,000
$	1.000		500,000		500,000
$	2.000		500,000		500,000
			7,750,000		7,550,000

The intrinsic value of exercisable but unexercised in-the-money stock options at March 31, 2019 was approximately $3,283,000, based on a fair market value of $0.90 per share on March 31, 2019.

Outstanding options to acquire 200,000 shares of the Company’s common stock had not vested at March 31, 2019.

The Company expects to satisfy such stock obligations through the issuance of authorized but unissued shares of common stock.

7. Commitments and Contingencies

Legal claims

The Company may be subject to legal claims and actions from time to time as part of its business activities. As of March 31, 2019, the Company was not subject to any pending or threatened legal claims or actions.

Significant agreements and contracts

Effective October 18, 2013, the Company entered into a Materials Cooperative Research and Development Agreement (M-CRADA) with the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH) for a term of four years. The Surgical Neurology Branch of NINDS is conducting research characterizing a variety of compounds proprietary to the Company and is examining the potential of the compounds for anti-cancer activity, reducing neurological deficit due to ischemia and brain injury, and stabilizing catalytic function of misfolded proteins for inborn brain diseases. Under an M-CRADA, a party provides research material, in this case proprietary compounds from the Company’s pipeline, for study by scientists at NIH. The exchange of material was for research only and did not imply any endorsement of the material on the part of either party. Under the M-CRADA, the NIH grants a collaborator an exclusive option to elect an exclusive or non-exclusive commercialization license.

On June 14, 2017, the Company executed Amendment No. 1 to the M-CRADA, pursuant to which the Company agreed to provide funding in the amount of $100,000 to the National Cancer Institute for use in acquiring technical, statistical and administrative support for research activities. The $100,000 amount was scheduled to be paid in two equal installments of $50,000, the first installment of which was paid, as scheduled, on July 9, 2017, and was charged to research and development costs in the consolidated statement of operations on such date. The second installment of $50,000 was scheduled to be paid on the June 14, 2018 anniversary date of the amendment and was accreted ratably through such date and included in research and development contract liabilities in the Company’s consolidated balance sheet. Pursuant to revised and updated collaboration plans, on November 3, 2018, the NINDS and the Company agreed to a cancellation of the second installment payment of $50,000. Accordingly, the previously accreted charge of $50,000, of which $25,000 was recorded during the six months ended June 30, 2018, was reversed during the fourth quarter of the year ended December 31, 2018. During the three months ended March 31, 2018, $12,500, was included in research and development costs in the consolidated statement of operations.

On December 24, 2013, the Company entered into an agreement with NDA Consulting Corp. (“NDA”) for consultation and advice in the field of oncology research and drug development. As part of the agreement, NDA also agreed to cause its president, Dr. Daniel D. Von Hoff, M.D., to become a member of the Company’s Scientific Advisory Committee. The term of the agreement was for one year and provided for a quarterly cash fee of $4,000. In 2014, 2015, 2016, 2017 and 2018, the agreement was automatically renewed on its anniversary date for an additional one-year term. Consulting and advisory fees charged to operations pursuant to this agreement were $4,000 during the three months ended March 31, 2019 and 2018.

Effective September 14, 2015, the Company entered into a Collaboration Agreement with BioPharmaWorks, pursuant to which the Company engaged BioPharmaWorks to perform certain services for the Company. Those services include, among other things: (a) assisting the Company to (i) commercialize its products and strengthen its patent portfolio, (ii) identify large pharmaceutical companies with potential interest in the Company’s product pipeline, and (iii) prepare and deliver presentations concerning the Company’s products; (b) at the request of the Board of Directors, serving as backup management for up to three months should the Company’s Chief Executive Officer and scientific leader be temporarily unable to carry out his duties; (c) being available for consultation in drug discovery and development; and (d) identifying providers and overseeing tasks relating to clinical use and commercialization of new compounds.

BioPharmaWorks was founded in 2015 by former Pfizer scientists with extensive multi-disciplinary research and development and drug development experience. The Collaboration Agreement was for an initial term of two years and automatically renews for subsequent annual periods unless terminated by a party not less than 60 days prior to the expiration of the applicable period. In connection with the Collaboration Agreement, the Company agreed to pay BioPharmaWorks a monthly fee of $10,000, subject to the right of the Company to pay a negotiated hourly rate in lieu of the monthly payment and agreed to issue to BioPharmaWorks certain equity-based compensation. In November 2016, it was mutually agreed to suspend services and payments under the Collaboration Agreement, without extending its term, for the period from November 1, 2016 through March 31, 2017. The Collaboration Agreement resumed as scheduled on April 1, 2017 and was automatically renewed for additional one-year periods on September 13, 2017 and 2018, respectively. In April 2018, it was again mutually agreed to suspend services and payments under the Collaboration Agreement, without extending its term, for the period from February 1, 2018 through the September 13, 2019 anniversary date. In February 2019, the Company and BioPharmaWorks subsequently agreed to resume the Collaboration Agreement effective March 1, 2019. The Company recorded charges to operations pursuant to this Collaboration Agreement of $10,000 and $10,000, which were included in research and development costs in the consolidated statement of operations, during the three months ended March 31, 2019 and 2018, respectively.

On March 22, 2018, the Company entered into a Patent Assignment and Exploitation Agreement (the “Agreement”) with INSERM TRANSFERT SA, acting as delegatee of the French National Institute of Health and Medical Research (“INSERM”), for the assignment to the Company of INSERM’S interest in United States Patent No. 9,833,450 entitled “Oxabicyloheptanes and Oxabicycloheptenes for the Treatment of Depressive and Stress Disorders”, which was filed with the United States Patent and Trademark Office in the name of INSERM and the Company as co-owners on February 19, 2015 and granted on May 12, 2017, and related patent applications and filings. INSERM is a French public institution dedicated to research in the field of health and medicine that had previously entered into a Material Transfer Agreement (“MTA”) with the Company to allow INSERM to conduct research on the Company’s proprietary compound LB-100 and/or its analogs for the treatment of depressive or stress disorders in humans. Pursuant to the Agreement, the Company has agreed to make certain milestone payments to INSERM aggregating up to $1,750,000 upon achievement of development milestones and up to $6,500,000 upon achievement of commercial milestones. The Company also agreed to pay INSERM certain commercial royalties on net sales of products attributed to the Agreement. The Company’s current plan is to complete the validation process to evaluate LB-100 for the treatment of depressive or stress disorders in humans within three years; however, the exploitation of this patent for the treatment of depressive and stress disorders in humans will require substantial additional capital and/or a joint venture or other type of business arrangement with a pharmaceutical company with substantially greater capital and business resources than those available to the Company. As there can be no assurances that the Company will be able to obtain the capital or business resources necessary to focus on the exploitation of this patent, it is uncertain when the Company may reach any of the development or commercialization milestones under the Agreement, if at all.

Effective April 2, 2018, the Company entered into a consulting agreement for a term of two years with Liberi Life Sciences Consultancy BV, located in The Netherlands, for consulting and advisory services with respect to sales and licensing, as well as the procurement of investors in China, Japan and South Korea (the “Consulting Agreement”). The Consulting Agreement provided for the payment of a fixed, one-time retainer of EURO 15,000 (US $18,348), which was paid on April 5, 2018, and 2.5% of the net payments received by the Company from sales of products or licensing activities arising directly and exclusively from leads generated by the advisor during the term of the Consulting Agreement, and any investors introduced to the Company by the advisor that results in an investment in the Company during the term of the Consulting Agreement. The Company recorded the payment of the retainer as a prepaid expense in the Company’s consolidated balance sheet. The Company is amortizing the retainer payment over the two-year life of the Consulting Agreement, as a result of which the Company recorded a charge to operations of $2,294 during the three months ended March 31, 2019. At March 31, 2019, the unamortized balance of the retainer payment was $9,174, all of which was classified as a current asset in the Company’s consolidated balance sheet at such date. At December 31, 2018, the unamortized balance of the retainer payment was $11,468, of which $9,175 was classified as a current asset and $2,293 was classified as a non-current asset in the Company’s consolidated balance sheet at such date.

Effective August 20, 2018 (the “Effective Date”), the Company and the Moffitt Cancer Center and Research Institute Hospital Inc., Tampa, Florida (“Moffitt”) entered into an Exclusive License Agreement (the “License Agreement”). Pursuant to the License Agreement, Moffitt granted the Company an exclusive license under certain patents owned by Moffitt (the “Licensed Patents”) relating to the treatment of MDS and a non-exclusive license under inventions, concepts, processes, information, data, know-how, research results, clinical data, and the like (other than the Licensed Patents) necessary or useful for the practice of any claim under the Licensed Patents or the use, development, manufacture or sale of any product for the treatment of MDS which would otherwise infringe a valid claim under the Licensed Patents. The Company is obligated to pay Moffitt a non-refundable license issue fee of $25,000 after the first patient is entered into a Phase 1b/2 clinical trial to be managed and conducted by Moffitt. This clinical trial began during April 2019. The Company is also obligated to pay Moffitt an annual license maintenance fee of $25,000 commencing on the first anniversary of the Effective Date and every anniversary thereafter until the Company commences payment of minimum royalty payments. The Company has also agreed to pay non-refundable milestone payments to Moffitt, which cannot be credited against earned royalties payable by the Company, based on reaching various clinical and commercial milestones aggregating $1,897,000, subject to reduction by 40% under certain circumstances relating to the status of Valid Claims, as such term is defined in the License Agreement. During the three months ended March 31, 2019, the Company recorded a charge to operations of $15,274 in connection with these license agreements.

The Company will be obligated to pay Moffitt earned royalties of 4% on worldwide cumulative net sales of royalty-bearing products, subject to reduction to 2% under certain circumstances, on a quarterly basis, with a minimum royalty payment of $50,000 in the first four years after sales commence, and $100,000 in year five and each year thereafter, subject to reduction by 40% under certain circumstances relating to the status of Valid Claims, as such term is defined in the License Agreement. The Company’s obligation to pay earned royalties under the License Agreement commences on the date of the first sale of a royalty-bearing product, and shall automatically expire on a country-by-country basis on the date on which the last valid claim of the Licensed Patents expires, lapses or is declared invalid, and the obligation to pay any earned royalties under the License Agreement shall terminate on the date on which the last valid claim of the Licensed Patents expires, lapses, or is declared to be invalid in all countries.

Effective August 20, 2018, the Company and Moffitt also entered into a Clinical Trial Research Agreement (the “Clinical Trial Research Agreement”) effective for a term of five years, unless terminated earlier by the Company pursuant to 30 days written notice. Pursuant to the Clinical Trial Research Agreement, Moffitt will conduct and manage a Phase 1b/2 clinical trial to evaluate the therapeutic benefit of the Company’s lead anti-cancer clinical compound LB-100 to be administered intravenously in patients with low or intermediate-1 risk MDS.

In early November 2018, the Company received approval from the FDA for its Investigational New Drug (IND) Application to conduct a Phase 1b/2 clinical trial to evaluate the therapeutic benefit of the Company’s lead clinical compound LB-100 in patients with low and intermediate-1 risk myelodysplastic syndrome (MDS) who have failed or are intolerant of standard treatment. This clinical trial began during April 2019 and is expected to complete patient accrual over a period of two years, with final analysis and reporting expected within three years.

On September 12, 2018, the Company finalized a work order agreement with Theradex to monitor the Phase 1b/2 clinical trial being conducted by Moffitt that began during April 2019. The clinical trial will be managed and conducted by Moffitt to evaluate the therapeutic benefit of the Company’s lead anti-cancer clinical compound LB-100 administered intravenously in patients with low or intermediate-1 risk MDS. This work order agreement became operational in August 2018 and is estimated to be completed by December 2021. Costs under this work order agreement are estimated to be approximately $954,000. During the three months ended March 31, 2019, the Company paid Theradex $32,964 pursuant to this work order. As of March 31, 2019, total costs of $44,870 have been incurred pursuant to this work order agreement.

8. Subsequent Events

Effective March 8, 2019, the Company entered into a Master Services Agreement with Triligent International (“Triligent”) for services associated with certain of the Company’s projected, current and/or future pre-clinical and/or clinical studies, for a period of three years and renewable for an additional three-year term, and terminable by either party. Triligent will invoice the Company for time and expenses on a monthly basis.

Effective April 5, 2019, pursuant to the terms of the Master Services Agreement, the Company finalized a work order agreement with Triligent to assist the Company in pre-study commencement medical writing projects, including the development of study protocols and model informed consent forms in connection with a clinical research proposal. The total cost of this work order is not expected to exceed $10,500.

Effective April 9, 2019, the Company entered into a consulting agreement with Theradex for consulting services associated with the Company’s worldwide development of LB-100, which is expected to be completed by July 1, 2020. Pursuant to the terms of the consulting agreement, Theradex will invoice the Company for time and expenses on a monthly basis.

The Company performed an evaluation of subsequent events through the date of filing of these consolidated financial statements with the SEC. There were no material subsequent events which affected, or could affect, the amounts or disclosures in the consolidated financial statements.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Overview

The Company’s common stock is traded on the OTCQB operated by the OTC Markets under the symbol “LIXT”.

Going Concern

At March 31, 2019, the Company had cash and cash equivalents of $3,893,604 available to fund its operations. The next step in the development of the Company’s lead anti-cancer clinical compound LB-100 is to evaluate its therapeutic benefit in a Phase 1b/2 clinical trial. This clinical trial began during April 2019 and is expected to complete patient accrual over a period of two years, with final analysis and reporting expected within three years. The Company’s longer-term objective is to secure one or more strategic partnerships with pharmaceutical companies with major programs in cancer.

Recent Accounting Pronouncements

Information with respect to recent accounting pronouncements is provided at Note 3 to the condensed consolidated financial statements for the three months ended March 31, 2019 and 2018 included elsewhere in this document.

Concentration of Risk

Information with respect to concentration of risk is provided at Note 3 to the condensed consolidated financial statements for the three months ended March 31, 2019 and 2018 included elsewhere in this document.

Critical Accounting Policies and Estimates

The preparation of the Company’s consolidated financial statements in conformity with generally accepted accounting principles in the United States (“GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and the notes to the consolidated financial statements. Some of those judgments can be subjective and complex, and therefore, actual results could differ materially from those estimates under different assumptions or conditions.

The following critical accounting policies affect the more significant judgements and estimates used in the preparation of the Company’s consolidated financial statements.

Research and Development

Patent and Licensing Costs

Stock-Based Compensation

Stock grants, which are generally time vested, are measured at the grant date fair value and charged to operations ratably over the vesting period.

Plan of Operation

Overview of Plans

The Company has two classes of drugs under development for the treatment of cancer, consisting of protein phosphatase inhibitors (PTase-i), designated by the Company as the LB-100 series of compounds, and histone deacetylase inhibitors (HDACi), designated by the Company as the LB-200 series of compounds. Compounds of both types also have potential use in the prevention and treatment of neurodegenerative diseases. The LB-100 series consists of novel structures, which have the potential to be first in their class and may be useful in the treatment of not only several types of cancer, but also vascular and metabolic diseases. The LB-200 series contains compounds which have the potential to be the most effective in its class and may be useful for the treatment of chronic hereditary diseases, such as Gaucher’s disease, in addition to cancer and neurodegenerative diseases.

The Company completed a Phase 1 clinical of its lead anti-cancer compound LB-100 that showed it is associated with anti-tumor activity in humans at doses that are readily tolerable. Responses included objective regression (tumor shrinkage) lasting for 11 months of a pancreatic cancer and cessation of growth (stabilization of disease) for 4 months or more of 9 other progressive solid tumors out of 20 patients who had measurable disease. As Phase 1 clinical trials are fundamentally designed to determine safety of a new compound in humans, the Company was encouraged by these results. The next step is to demonstrate in Phase 2 clinical trials the efficacy of LB-100 in one or more specific tumor types, against which the compound has well documented activity in pre-clinical models.

Collaborations with leading academic research centers in the United States, Europe and Asia have established the breadth of activity of LB-100 in pre-clinical models of several major cancers. There is considerable scientific interest in LB-100 because it exerts its activity by a novel mechanism and is the first of its type to be evaluated so broadly in multiple animal models of cancer and now in human beings. LB-100 is one a series of serine/threonine phosphatase (s/t ptase) inhibitors designed by the Company. The s/t ptases are ubiquitous enzymes that regulate many cell signaling networks important to cell growth, division and death. The s/t ptases have long been appreciated as potentially important targets for anti-cancer drugs. However, because of the multi- functionality of these enzymes, it had been widely held that pharmacologic inhibitors of s/t ptases would be too toxic to allow their development as anti-cancer treatments, but the Company has shown that this is not the case. LB-100 was well tolerated at doses associated with objective regression (significant tumor shrinkage) and/or the arresting of tumor progression in patients with progressive cancers.

Pre-clinical studies showed that LB-100 itself inhibits a spectrum of human cancers and that combined with standard cytotoxic drugs and/or radiation, LB-100 potentiates their effectiveness against hematologic and solid tumor cancers without enhancing toxicity. Recently, given at very low doses in animal models of cancer, LB-100 markedly increased the effectiveness of a PD-1 blocker, one of the widely used new immunotherapy drugs. This finding raises the possibility that LB-100 may further expand the value of the expanding field of cancer immunotherapy.

Although the Company’s focus has been on developing drugs for cancer treatment, several academic centers studying LB-100 under material transfer agreements with the Company have generated pre-clinical data indicating that LB-100 may be therapeutically effective in important non-neoplastic diseases. This development stems from the fact that dysregulation of the PP2A function is not only a feature of many cancers but is also a component of the basic inflammatory response elicited by diverse types of injury in animal models. These include lipid buildup in the blood vessels (type 2 diabetes), acute oxygen deprivation (myocardial infarction and stroke (MI/S)), and aversive physical and/or psychological trauma (depression and post traumatic shock-like syndromes.). The Company’s patent portfolio covers composition of matter for structurally distinct but comparably effective PP2A inhibitors and their use in the therapy of a broad spectrum of human diseases. However, the focus of the Company at this time is on demonstrating the value of LB-100 against specific cancers in humans.

At this time, the Company is not aware of any compound in clinical study that is a potent inhibitor of PP2A. Revlimid (Celgene) has recently been recognized to have weak PP2A activity, which presumably underlies its effects in myelodysplastic syndrome (MDS). Over 30 articles have been published reporting the anti-cancer activity of LB-100 against many different types of human cancers in model systems. As a result, the Company believes that some pharmaceutical companies are either evaluating LB-100 and/or designing their own inhibitors of PP2A. The Company’s patent portfolio includes composition of matter and multiple uses of LB-100 and analogs and PP2A inhibition in general for multiple cancers and non-neoplastic diseases.

The LB-200 series consists of histone deacetylase inhibitors (HDACi). Many pharmaceutical companies are also developing drugs of this type, and at least two companies have HDACi approved for clinical use, in both cases for the treatment of a type of lymphoma. Despite this significant competition, the Company has demonstrated that its HDACi have broad activity against many cancer types, has neuroprotective activity, and has anti-fungal activity. In addition, these compounds have low toxicity, making them attractive candidates for development. It appears that one type of molecule has diverse effects, affecting biochemical processes that are fundamental to the life of the cell, whether they are cancer cells, nerve cells, or even fungal cells. The neuroprotective activity of the Company’s HDACi has been demonstrated in the test tube in model systems that mimic injury to brain cells, such as occurs in stroke and Alzheimer’s disease. This type of protective activity may have potential application to a broad spectrum of other chronic neurodegenerative diseases, including Parkinson’s disease and Amytrophic Lateral Sclerosis (ALS, or Lou Gehrig’s disease). LB-200 has not yet advanced to the clinical stage and would require additional capital to fund further development. Accordingly, because of the Company’s focus on the clinical development of LB-100 and analogs for cancer therapy as described below in more detail, the Company has decided not to actively pursue the pre-clinical development of its LB-200 series of compounds at this time. At this time, the Company intends to only maintain its composition of matter patents for LB-200.

Operating Plans

LB-100 Anti-Cancer Targets and Recent Developments

LB-100 used alone has modest inhibitory activity against many cancers in model systems, but certain human cancers possessing unique genetic changes, in addition to those reducing DNA damage repair, are particularly susceptible to inhibition of PP2A by LB-100.

Among these cancers is MDS, an increasingly common neoplastic disease, especially in persons aged 65 and older, characterized by failure of the bone marrow. In particular, a variant of MDS termed del(5q)MDS is missing 50% of its PP2A activity, rendering this tumor potentially more sensitive to further pharmacologic inhibition of PP2A. There is only one drug, Revlimid (Celgene), that is currently approved for the treatment of del(5q)MDS and there is no drug for MDS in general.

Other cancers, in particular small cell lung cancer (SCLC) and hepatocellular cancer occurring in the liver (HCC), have acquired genetic abnormalities, which render them sensitive to inhibition of PP2A by a process termed synthetic lethality. Pre-clinical studies have shown that both SCLC and HCC are sensitive to PP2A inhibition by LB-100 alone and especially so when LB-100 is combined with drugs used as standard treatment for these diseases. SCLC the lung cancer variant associated with cigarette smoke and comprises about 15% of all lung cancers. HCC is the 5th most common cancer in the world and the 3rd leading cause of death from cancer, with the majority of cases being in Asia. There is no satisfactory treatment available for either of these devastating tumors.

Scientists at the National Institute of Neurological Disorders and Stroke (NINDS) have conducted pre-clinical studies of LB-100 that showed anti-cancer activity in models of a variety of human brain tumors, including glioblastomamultiforme (GBM), medulloblastoma and malignant meningioma. Studies of LB-100 and analogs in models of human brain tumors of adults and children are continuing under a Material-Cooperative Research and Development Agreement (M-CRADA) with the National Cancer Institute (NCI). The NCI has an FDA-approved clinical pharmacokinetic (non-therapeutic) study of LB-100 (Phase 0 Trial, NCT03027388) in patients with recurrent GBM to assess penetration of the compound into these highly malignant tumors. The rationale for this clinical study is that LB-100 potentiates the anti-tumor activity of both x-ray and the drug temozolomide, which are the mainstays of treatment for GBM.

Recent extensive pre-clinical studies of the Company’s lead PP2A inhibitor, LB-100, raise the possibility that LB-100 has the potential to enhance the effectiveness of the now widely used PD-1 inhibitors that attack a variety of cancers by activating the patient’s own immune system to reject their own tumors (Ho et al. (2018) Pharmacologic inhibition of protein phosphatase-2A achieves durable immune-mediated antitumor activity when combined with PD-1 blockade. Nature Communications (2018), 9:2126; Maggio et al. (2017) PD-1 Antagonism With Concurrent Competitive Inhibition Of PP2A Promotes Enhanced Regression Of Intracranial Glioblastoma. Neuro-Oncology, (2017) 19(6): vi75. DOI: 10.1093/neuonc/nox168.306). If these findings were confirmed in clinical studies, there could potentially be multiple clinical applications of combination therapy with a PD-1 inhibitor plus LB-100. In the animal models, there was no evidence that LB-100 potentiation of PD-100 immunological repression of cancers is accompanied by autoimmune toxicity to normal tissue targets.

In addition, an entirely new application of LB-100 to a specific class of hematologic cancers called B cell leukemias and lymphomas was reported by a group of hematological cancer experts from several national cancer centers in the journal Cell (Xiao et al. (2018) B-Cell-Specific Diversion of Glucose Carbon Utilization Reveals a Unique Vulnerability in B Cell Malignancies. Cell (2018) 173:1-15). The seminal finding was that B cell cancers in general require overexpression of PP2A for survival, and that in multiple pre-clinical models and in isolated human B cell cancers, LB-100 is highly inhibitory. The journal Cell is a peer-reviewed scientific journal publishing research papers across a broad range of disciplines within the life sciences. Although B cell cancer therapy is a crowded field with many treatments available, the discovery that these cancers are apparently dependent for survival on abnormally high levels of PP2A activity, the enzyme target of LB-100, merits further exploration of new regimens incorporating LB-100 for therapy of these diseases.

Near-Term Objectives

The Company’s immediate goals are to demonstrate significant therapeutic benefit of LB-100, the Company’s lead anti-cancer clinical compound, against one or more specific human cancers in Phase 2 clinical trials. The Company has several attractive targets for new therapies incorporating LB-100. The potentiation of cancer immunotherapy by adding LB-100 to regimens of PD-1 blockers, as reported by Ho et al (2018), and the unexpected findings of Muschen et al (2018) that a metabolic imbalance involving over activity of the enzyme PP2A in B cell cancers, which is the target of LB-100, may provide a selective advantage in the therapy of B cell cancers. These findings have also led the Company to reexamine the most attractive cancer targets for demonstrating the clinical effectiveness LB-100 and to enter into discussions with cancer centers that focus on the inhibition of PP2A as an important cancer target.

Effective August 20, 2018, the Company and the Moffitt Cancer Center and Research Institute Hospital Inc., Tampa, Florida (“Moffitt”) entered into a Clinical Trial Research Agreement (the “Clinical Trial Research Agreement”) effective for a term of five years, unless terminated earlier by the Company pursuant to 30 days written notice. Pursuant to the Clinical Trial Research Agreement, Moffitt will conduct and manage a Phase 1b/2 clinical trial to evaluate the therapeutic benefit of the Company’s lead anti-cancer clinical compound LB-100 to be administered intravenously in patients with low or intermediate-1 risk MDS. This clinical trial began during April 2019 and is expected to complete patient accrual over a period of two years, with final analysis and reporting expected within three years. This Phase 1b/2 clinical trial will utilize LB-100 as a single agent in the treatment of patients with del(5q) myelodysplastic syndrome (del5qMDS) failing first line therapy. The bone marrow cells of these patients are deficient in PP2A and are especially vulnerable to further inhibition of PP2A by LB-100.

Presented below are proposed clinical trials that the Company would like to conduct over the next few years. The Company expects that these potential clinical trials, and the details thereof, will change over time as the Company obtains more clinical information on LB-100. The Company’s ability to conduct these clinical trials is subject to the availability of sufficient financial resources.

(1) A Phase 1b/2 randomized clinical trial in previously untreated patients with small cell lung cancer (SCLC) comparing the standard regimen, carboplatin/etoposide, with and without LB-100. The malignant cells of this uniformly rapidly fatal lung cancer are genetically sensitive to PP2A inhibition (by a process termed synthetic lethality).

(2) A Phase 1b/2 randomized clinical trial in patients adding LB-100 to PD-1 inhibitors against one of several cancers in which PD-1 inhibitors alone have definite but modest activity.

The Phase 1b/2 clinical trials in SCLC and in LB-100 plus a PD-1 inhibitor in yet to be specified solid tumors will require additional financing in excess of that currently budgeted to fund a Phase 1b/2 clinical trial in myelodysplastic syndrome that began in April 2019 as described above, and/or partnering relationships with other pharmaceutical companies, in order for the Company to undertake and complete such clinical studies. The Company is in discussions with various parties with respect to the financing of these clinical studies, although there can be no assurances that the Company will be able to obtain such financing and/or partnering relationships on acceptable terms or at all. The Company’s longer-term objective is to secure one or more strategic partnerships with pharmaceutical companies with major programs in cancer research and drug development.

As a compound moves through the FDA-approval process, it becomes an increasingly valuable property, but at a cost of additional investment at each stage. As the potential effectiveness of LB-100 has been documented at the clinical trial level, the Company has allocated resources to expand the breadth and depth of its patent portfolio. The Company’s approach has been to operate with a minimum of overhead, moving compounds forward as efficiently and inexpensively as possible, and to raise funds to support each of these stages as certain milestones are reached.

Results of Operations

At March 31, 2019, the Company had not yet commenced any revenue-generating operations, does not have any positive cash flows from operations, and is dependent on its ability to raise equity capital to fund its operating requirements.

The Company’s condensed consolidated statements of operations as discussed herein are presented below.

	Three Months Ended March 31,
	2019			2018

Revenues	$	—		$	—

Costs and expenses:
General and administrative costs		390,428			354,070
Research and development costs		48,314			25,689
Total costs and expenses		438,742			379,759
Loss from operations		(438,742	)		(379,759	)
Interest income		10,006			599
Net loss	$	(428,736	)	$	(379,160	)

Net loss per common share – basic and diluted	$	(0.01	)	$	(0.01	)

Weighted average common shares outstanding – basic and diluted		67,045,814			58,025,814

Three Months Ended March 31, 2019 and 2018

Revenues. The Company did not have any revenues for the three months ended March 31, 2019 and 2018.

General and Administrative Costs. For the three months ended March 31, 2019, general and administrative costs were $390,428, which consisted of patent and licensing legal fees and costs of $190,773, other consulting and professional fees of $125,461, the fair value of vested stock options issued to directors of $12,936, insurance expense of $13,546, officer’s salary and related costs of $17,028, licensing fees of $15,274, stock transfer fees of $3,345, listing fees of $3,000, filing fees of $5,000, and other operating costs of $4,065.

For the three months ended March 31, 2018, general and administrative costs were $354,070, which consisted of patent and licensing legal fees and costs of $217,659, other consulting and professional fees of $90,246, insurance expense of $12,796, officer’s salary and related costs of $16,965, stock transfer fees of $3,924, listing fees of $3,000, filing fees of $6,294, and other operating costs of $3,186.

General and administrative costs increased by $36,358 or 10.3% in 2019 as compared to 2018, primarily as a result of an increase in other consulting and professional fees of $35,215, licensing fees of $15,274 and the fair value of stock options issued to directors of $12,936, offset by a decrease in patent and licensing fees of $26,886

Research and Development Costs. For the three months ended March 31, 2019, research and development costs were $48,314, which consisted entirely of contractor costs, primarily in connection with the Company’s pre-clinical research focused on the development of additional novel anti-cancer compounds to add to its clinical pipeline, including $32,964 to Theradex in connection with the Phase 1b/2 clinical trial of LB-100, and $10,000 to BioPharma Works.

For the three months ended March 31, 2018, research and development costs were $25,689, which consisted entirely of contractor costs, primarily in connection with the Company’s pre-clinical research focused on the development of additional novel anti-cancer compounds to add to its clinical pipeline, including $10,000 to BioPharma Works, and $12,500 to the National Cancer Institute in connection with Amendment No. 1 to the M-CRADA.

Research and development costs increased by $22,625 or 88.1% in 2019 as compared to 2018, as a result of an increase in contractor costs primarily to Theradex in connection with the Phase 1b/2 clinical trial of LB-100.

Interest Income. For the three months ended March 31, 2019, the Company had interest income of $10,006, as compared to interest income of $599 for the three months ended March 31, 2018, as a result of the Company investing the majority of its cash resources in short-term federally insured certificates of deposit beginning in 2019.

Net Loss. For the three months ended March 31, 2019, the Company incurred a net loss of $428,736, as compared to a net loss of $379,160 for the three months ended March 31, 2018.

Liquidity and Capital Resources – March 31, 2019

The Company’s condensed consolidated financial statements have been presented on the basis that it is a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has not generated any revenues from operations to date and does not expect to do so in the foreseeable future. Furthermore, the Company has experienced recurring operating losses and negative operating cash flows since inception and has financed its working capital requirements during this period primarily through the recurring sale of its equity securities and the exercise of outstanding common stock options and purchase warrants. As a result, management has concluded that there is substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the condensed consolidated financial statements are being issued. In addition, the Company’s independent registered public accounting firm, in their report on the Company’s consolidated financial statements for the year ended December 31, 2018, has also expressed substantial doubt about the Company’s ability to continue as a going concern (see “Going Concern” above).

At March 31, 2019, the Company had working capital of $3,710,023, as compared to working capital of $4,123,530 at December 31, 2018, reflecting a decrease in working capital of $413,507 for the three months ended March 31, 2019. The decrease in working capital during the three months ended March 31, 2019 was the result of working capital being utilized to fund the Company’s research and development activities and ongoing operating expenses, including maintaining and developing the Company’s patent portfolio.

Operating Activities. For the three months ended March 31, 2019, operating activities utilized cash of $379,408, as compared to utilizing cash of $497,710 for the three months ended March 31, 2018, to fund the Company’s ongoing research and development activities and to fund its other ongoing operating expenses, including maintaining and developing its patent portfolio.

Investing Activities. For the three months ended March 31, 2019 and 2018, the Company had no investing activities.

Financing Activities. For the three months ended March 31, 2019 and 2018, the Company had no financing activities.

Principal Commitments

BioPharmaWorks was founded in 2015 by former Pfizer scientists with extensive multi-disciplinary research and development and drug development experience. The Collaboration Agreement was for an initial term of two years and automatically renews for subsequent annual periods unless terminated by a party not less than 60 days prior to the expiration of the applicable period. In connection with the Collaboration Agreement, the Company agreed to pay BioPharmaWorks a monthly fee of $10,000, subject to the right of the Company to pay a negotiated hourly rate in lieu of the monthly payment and agreed to issue to BioPharmaWorks certain equity-based compensation. In November 2016, it was mutually agreed to suspend services and payments under the Collaboration Agreement, without extending its term, for the period from November 1, 2016 through March 31, 2017. The Collaboration Agreement resumed as scheduled on April 1, 2017 and was automatically renewed for additional one-year periods on September 13, 2017 and 2018, respectively. In April 2018, it was again mutually agreed to suspend services and payments under the Collaboration Agreement, without extending its term, for the period from February 1, 2018 through the September 13, 2019 anniversary date. In February 2019, the Company and BioPharmaWorks subsequently agreed to resume the Collaboration Agreement effective March 1, 2019. The Company recorded charges to operations pursuant to this Collaboration Agreement of $10,000 and $10,000 during the three months ended March 31, 2019 and 2018, respectively, which were included in research and development costs in the consolidated statement of operations.

Off-Balance Sheet Arrangements

At March 31, 2019, the Company did not have any transactions, obligations or relationships that could be considered off-balance sheet arrangements.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK

Not applicable.

ITEM 4. CONTROLS AND PROCEDURES

(a) Evaluation of Disclosure Controls and Procedures

The Company carried out an evaluation, under the supervision and with the participation of its management, consisting of its principal executive officer and principal financial officer (who is the same person), of the effectiveness of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act (defined below)). Based upon that evaluation, the Company’s principal executive officer and principal financial officer concluded that, as of the end of the period covered in this report, the Company’s disclosure controls and procedures were effective to ensure that information required to be disclosed in reports filed under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is recorded, processed, summarized and reported within the required time periods and is accumulated and communicated to the Company’s management, consisting of the Company’s principal executive officer and principal financial officer, to allow timely decisions regarding required disclosure.

The Company’s management, consisting of its principal executive officer and principal financial officer, does not expect that its disclosure controls and procedures or its internal controls will prevent all error or fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Furthermore, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs. Due to the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. In addition, as conditions change over time, so too may the effectiveness of internal controls. However, management believes that the consolidated financial statements included in this report fairly present, in all material respects, the Company’s financial condition, results of operations and cash flows for the periods presented.

(b) Changes in Internal Controls Over Financial Reporting

The Company’s management, consisting of its principal executive officer and principal financial officer, has determined that no change in the Company’s internal control over financial reporting (as that term is defined in Rules 13(a)-15(f) and 15(d)-15(f) of the Securities Exchange Act of 1934) occurred during or subsequent to the end of the period covered in this report that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

The Company is not currently subject to any pending or threatened legal actions or claims.

ITEM 1A. RISK FACTORS

As of the date of this filing, there have been no material changes to the Risk Factors included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018, as filed with the Securities and Exchange Commission on March 25, 2019 (the “2018 Form 10-K”). The Risk Factors set forth in the 2018 Form 10-K should be read carefully in connection with evaluating the Company’s business and in connection with the forward-looking statements contained in this Quarterly Report on Form 10-Q. Any of the risks described in the 2018 Form 10-K could materially adversely affect the Company’s business, financial condition or future results and the actual outcome of matters as to which forward-looking statements are made. These are not the only risks that the Company faces. Additional risks and uncertainties not currently known to the Company or that the Company currently deems to be immaterial also may materially adversely affect the Company’s business, financial condition and/or operating results.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Not applicable.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

Not applicable.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

Not applicable.

ITEM 6. EXHIBITS

A list of exhibits required to be filed as part of this report is set forth in the Index to Exhibits, which is presented elsewhere in this document, and is incorporated herein by reference.

SIGNATURES

In accordance with the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	LIXTE BIOTECHNOLOGY HOLDINGS, INC.
	(Registrant)

Date: May 9, 2019	By:	/s/ JOHN S. KOVACH
		John S. Kovach
		Chief Executive Officer and Chief Financial Officer
		(Principal financial and accounting officer)

INDEX TO EXHIBITS

The following documents are filed as part of this report:

Exhibit Number		Description of Document

31.1*		Officer’s Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1*		Officer’s Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS**		XBRL Instance Document

101.SCH**		XBRL Taxonomy Extension Schema Document

101.CAL**		XBRL Taxonomy Extension Calculation Linkbase Document

101.LAB**		XBRL Taxonomy Extension Label Linkbase Document

101.PRE**		XBRL Taxonomy Extension Presentation Linkbase Document

101.DEF**		XBRL Taxonomy Extension Definition Linkbase Document

* Filed herewith.

** In accordance with Regulation S-T, the XBRL related information on Exhibit No. 101 to this Quarterly Report on Form 10-Q shall be deemed “furnished” herewith but not “filed”.

EX-31.1 2 ex31-1.htm

Exhibit 31.1

CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER

UNDER SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, John S. Kovach, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Lixte Biotechnology Holdings, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)), for the registrant and have:

	(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared;

	(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	(d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s Board of Directors (or persons performing the equivalent functions):

	(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 9, 2019	By:	/s/ JOHN S. KOVACH
		John S. Kovach
		Chief Executive Officer and Chief Financial Officer

EX-32.1 3 ex32-1.htm

Exhibit 32.1

CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER
UNDER SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, John S. Kovach, the Chief Executive Officer and Chief Financial Officer of Lixte Biotechnology Holdings, Inc. (the “Company”), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:

(i) The Quarterly Report on Form 10-Q of the Company for the quarterly period ended March 31, 2019 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and

(ii) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

Date: May 9, 2019	By:	/s/ JOHN S. KOVACH
		John S. Kovach
		Chief Executive Officer and Chief Financial Officer

EX-101.INS 4 lixt-20190331.xml XBRL INSTANCE FILE 0001335105 2019-01-01 2019-03-31 0001335105 2019-03-31 0001335105 LIXT:TwoThousandSevenStockCompensationPlanMember 2007-06-19 2007-06-20 0001335105 LIXT:TwoThousandSevenStockCompensationPlanMember 2019-01-01 2019-03-31 0001335105 LIXT:NDAConsultingCorpMember 2013-12-23 2013-12-24 0001335105 LIXT:BioPharmaWorksLLCMember 2015-09-13 2015-09-14 0001335105 us-gaap:CommonStockMember 2017-12-31 0001335105 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001335105 us-gaap:RetainedEarningsMember 2017-12-31 0001335105 LIXT:MaterialsCooperativeResearchandDevelopmentAgreementMember 2017-06-13 2017-06-14 0001335105 LIXT:MaterialsCooperativeResearchandDevelopmentAgreementMember 2018-01-01 2018-03-31 0001335105 LIXT:ConsultingAgreementMember LIXT:MrSchwartzbergMember 2014-01-26 2014-01-28 0001335105 LIXT:ConsultingAgreementMember LIXT:MrSchwartzbergMember 2014-01-28 0001335105 LIXT:ConsultingAgreementMember LIXT:MrSchwartzbergMember 2015-01-28 0001335105 2018-01-01 2018-03-31 0001335105 2018-12-31 0001335105 us-gaap:CommonStockMember 2018-12-31 0001335105 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001335105 us-gaap:RetainedEarningsMember 2018-12-31 0001335105 us-gaap:EmployeeStockOptionMember 2018-12-31 0001335105 LIXT:MaterialTransferAgreementMember LIXT:INSERMMember LIXT:DevelopmentMilestonesMember srt:MaximumMember 2018-03-21 2018-03-22 0001335105 LIXT:MaterialTransferAgreementMember LIXT:INSERMMember LIXT:CommercialMilestonesMember srt:MaximumMember 2018-03-21 2018-03-22 0001335105 LIXT:MaterialsCooperativeResearchandDevelopmentAgreementMember LIXT:FirstinstallmentMember 2017-07-08 2017-07-09 0001335105 LIXT:MaterialsCooperativeResearchandDevelopmentAgreementMember LIXT:SecondInstallmentMember 2018-06-13 2018-06-14 0001335105 LIXT:SeriesAConvertiblePreferredStockMember 2018-12-31 0001335105 LIXT:SeriesAConvertiblePreferredStockMember 2019-03-31 0001335105 LIXT:ConsultingAgreementWithLiberiLifeConsultancyBVMember LIXT:EURMember 2018-04-04 2018-04-05 0001335105 LIXT:ConsultingAgreementWithLiberiLifeConsultancyBVMember 2018-04-04 2018-04-05 0001335105 LIXT:ConsultingAgreementMember LIXT:MrSchwartzbergMember 2018-08-01 2018-08-02 0001335105 LIXT:WinsonSzeChunHoMember 2018-08-03 2018-08-04 0001335105 LIXT:WinsonSzeChunHoMember 2018-08-04 0001335105 LIXT:DrYunYenMember 2018-08-03 2018-08-04 0001335105 LIXT:DrYunYenMember 2018-08-04 0001335105 LIXT:DrYunYenMember LIXT:AugustFourTwoThousandAndNineteenMember 2019-01-01 2019-03-31 0001335105 LIXT:WinsonSzeChunHoMember 2019-01-01 2019-03-31 0001335105 LIXT:DrYunYenMember 2019-01-01 2019-03-31 0001335105 LIXT:FirstFourYearsMember 2018-01-01 2018-12-31 0001335105 LIXT:FiveYearsAndThereafterMember 2018-01-01 2018-12-31 0001335105 LIXT:WorkOrderAgreementMember LIXT:TheradexSystemsIncMember 2018-09-11 2018-09-12 0001335105 LIXT:SixteenAccreditedInvestorsMember 2018-11-29 2018-11-30 0001335105 LIXT:SixteenAccreditedInvestorsMember 2018-11-30 0001335105 LIXT:CommonStockWarrantsMember 2018-12-31 0001335105 LIXT:MaterialsCooperativeResearchandDevelopmentAgreementMember LIXT:SecondInstallmentMember 2018-11-02 2018-11-03 0001335105 2018-01-01 2018-06-30 0001335105 LIXT:ConsultingAgreementWithLiberiLifeConsultancyBVMember 2018-04-01 2018-04-02 0001335105 LIXT:TwoThousandSevenStockCompensationPlanMember 2019-03-31 0001335105 2019-05-01 0001335105 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001335105 us-gaap:CommonStockMember 2019-03-31 0001335105 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001335105 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001335105 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001335105 us-gaap:RetainedEarningsMember 2019-03-31 0001335105 2017-12-31 0001335105 2018-03-31 0001335105 us-gaap:SubsequentEventMember srt:MaximumMember 2019-04-04 2019-04-05 0001335105 LIXT:NDAConsultingCorpMember 2018-01-01 2018-03-31 0001335105 LIXT:NDAConsultingCorpMember 2019-01-01 2019-03-31 0001335105 LIXT:BioPharmaWorksLLCMember 2019-01-01 2019-03-31 0001335105 LIXT:BioPharmaWorksLLCMember 2018-01-01 2018-03-31 0001335105 LIXT:LicenseAgreementMember 2019-01-01 2019-03-31 0001335105 LIXT:MoffittCancerCenterandResearchInstituteHospitalIncMember LIXT:LicenseAgreementMember 2018-08-19 2018-08-20 0001335105 LIXT:MoffittCancerCenterandResearchInstituteHospitalIncMember LIXT:LicenseAgreementMember 2018-08-20 0001335105 LIXT:WorkOrderAgreementMember LIXT:TheradexSystemsIncMember 2019-01-01 2019-03-31 0001335105 LIXT:SeriesAConvertiblePreferredStockMember 2019-01-01 2019-03-31 0001335105 LIXT:TheradexSystemsIncMember 2019-01-01 2019-03-31 0001335105 LIXT:SeriesAConvertiblePreferredStockMember 2019-01-01 2019-03-31 0001335105 LIXT:CommonStockWarrantsMember 2019-01-01 2019-03-31 0001335105 LIXT:CommonStockOptionsIncludingOptionsIssuedintheFormofWarrantsMember 2019-01-01 2019-03-31 0001335105 LIXT:SeriesAConvertiblePreferredStockMember 2018-01-01 2018-03-31 0001335105 LIXT:CommonStockWarrantsMember 2018-01-01 2018-03-31 0001335105 LIXT:CommonStockOptionsIncludingOptionsIssuedintheFormofWarrantsMember 2018-01-01 2018-03-31 0001335105 LIXT:SeriesAConvertiblePreferredStockMember 2015-03-17 0001335105 LIXT:SeriesAConvertiblePreferredStockMember 2015-03-16 2015-03-17 0001335105 LIXT:SeriesAConvertiblePreferredStockMember srt:MaximumMember 2016-01-28 0001335105 us-gaap:PreferredStockMember 2019-03-31 0001335105 LIXT:CommonStockWarrantMember 2019-01-01 2019-03-31 0001335105 LIXT:CommonStockWarrantMember 2019-03-31 0001335105 LIXT:CommonStockWarrantsMember 2019-01-01 2019-03-31 0001335105 LIXT:CommonStockWarrantsMember 2019-03-31 0001335105 LIXT:Dr.JohnKovachMember 2019-01-01 2019-03-31 0001335105 LIXT:Dr.JohnKovachMember 2018-01-01 2018-03-31 0001335105 LIXT:EricFormanMember 2019-01-01 2019-03-31 0001335105 LIXT:EricFormanMember 2018-01-01 2018-03-31 0001335105 LIXT:DirectorsAndOfficersMember 2019-01-01 2019-03-31 0001335105 LIXT:DirectorsAndOfficersMember 2018-01-01 2018-03-31 0001335105 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-03-31 0001335105 us-gaap:EmployeeStockOptionMember 2019-03-31 0001335105 LIXT:ExercisePriceOneMember 2019-01-01 2019-03-31 0001335105 LIXT:ExercisePriceOneMember 2019-03-31 0001335105 LIXT:ExercisePriceTwoMember 2019-01-01 2019-03-31 0001335105 LIXT:ExercisePriceTwoMember 2019-03-31 0001335105 LIXT:ExercisePriceThreeMember 2019-01-01 2019-03-31 0001335105 LIXT:ExercisePriceThreeMember 2019-03-31 0001335105 LIXT:ExercisePriceFourMember 2019-01-01 2019-03-31 0001335105 LIXT:ExercisePriceFourMember 2019-03-31 0001335105 LIXT:ExercisePriceFiveMember 2019-01-01 2019-03-31 0001335105 LIXT:ExercisePriceFiveMember 2019-03-31 0001335105 LIXT:ExercisePriceSixMember 2019-01-01 2019-03-31 0001335105 LIXT:ExercisePriceSixMember 2019-03-31 0001335105 LIXT:ExercisePriceSevenMember 2019-01-01 2019-03-31 0001335105 LIXT:ExercisePriceSevenMember 2019-03-31 0001335105 LIXT:ExercisePriceEightMember 2019-01-01 2019-03-31 0001335105 LIXT:ExercisePriceEightMember 2019-03-31 0001335105 LIXT:ExercisePriceNineMember 2019-01-01 2019-03-31 0001335105 LIXT:ExercisePriceNineMember 2019-03-31 0001335105 LIXT:SeriesAConvertiblePreferredStockMember srt:MinimumMember 2016-01-28 0001335105 LIXT:WinsonSzeChunHoMember LIXT:AugustFourTwoThousandAndNineteenMember 2018-08-03 2018-08-04 0001335105 LIXT:SeriesAConvertiblePreferredStockMember 2018-01-01 2018-03-31 0001335105 LIXT:SeriesAConvertiblePreferredStockMember 2017-12-31 0001335105 LIXT:SeriesAConvertiblePreferredStockMember 2018-03-31 0001335105 us-gaap:CommonStockMember 2018-01-01 2018-03-31 0001335105 us-gaap:CommonStockMember 2018-03-31 0001335105 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-03-31 0001335105 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0001335105 us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0001335105 us-gaap:RetainedEarningsMember 2018-03-31 xbrli:shares iso4217:USD xbrli:shares iso4217:USD xbrli:pure iso4217:EUR 2019-03-31 false --12-31 Non-accelerated Filer

0.0001

10000000

175000

350000

175000

-428736

-379160

-428736

-379160

LIXT

50.00

LIXTE BIOTECHNOLOGY HOLDINGS, INC. Q1

58025814

67045814

350000

67045814

350000

58025814

3710023

5802

20004654

-22515415

4125823

6704

25267662

-24648543

3500000

6704

25280598

-25077279

995041

615881

3500000

5802

20004654

-22894575

10-Q

A summary of stock option activity, including options issued in the form of warrants, during the three months ended March 31, 2019 is presented below.   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Number of Shares</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Weighted Average Exercise Price</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Weighted Average Remaining Contractual Life (in Years)</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 50%; line-height: 107%">Stock options outstanding at December 31, 2018</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 14%; text-align: right; line-height: 107%">7,750,000</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 13%; text-align: right; line-height: 107%">0.583</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 13%; text-align: right; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Granted</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">—</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">—</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Exercised</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">—</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">—</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Expired</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">—</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">—</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Stock options outstanding at March 31, 2019</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">7,750,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">0.538</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">3.43</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Stock options exercisable at March 31, 2019</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">7,550,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">0.545</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">3.41</td> <td style="line-height: 107%"> </td></tr> </table>

The exercise prices of common stock options outstanding and exercisable, including options issued in the form of warrants, are as follows at March 31, 2019:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Exercise  Prices</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Options  Outstanding (Shares)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Options Exercisable (Shares)</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 34%; text-align: right; line-height: 107%">0.120</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 29%; text-align: right; line-height: 107%">450,000</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 29%; text-align: right; line-height: 107%">450,000</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.150</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">300,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">300,000</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.160</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">200,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">200,000</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.200</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">500,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">500,000</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.250</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">500,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">500,000</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.280</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">400,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">200,000</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.500</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">4,400,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">4,400,000</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">1.000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">500,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">500,000</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">2.000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">500,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">500,000</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">7,750,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">7,550,000</td> <td style="line-height: 107%"> </td></tr> </table>

48314

12500

25689

10000

2019

2500000

1250000

4000000

200000

100000

104920 104920

52460

0.2623

12936

P5Y

0.28

12936

18000

7750000

1250000

7750000

12000

33897 0

7. Commitments and Contingencies   Legal claims   The Company may be subject to legal claims and actions from time to time as part of its business activities. As of March 31, 2019, the Company was not subject to any pending or threatened legal claims or actions.   Significant agreements and contracts   Effective October 18, 2013, the Company entered into a Materials Cooperative Research and Development Agreement (M-CRADA) with the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH) for a term of four years. The Surgical Neurology Branch of NINDS is conducting research characterizing a variety of compounds proprietary to the Company and is examining the potential of the compounds for anti-cancer activity, reducing neurological deficit due to ischemia and brain injury, and stabilizing catalytic function of misfolded proteins for inborn brain diseases. Under an M-CRADA, a party provides research material, in this case proprietary compounds from the Company’s pipeline, for study by scientists at NIH. The exchange of material was for research only and did not imply any endorsement of the material on the part of either party. Under the M-CRADA, the NIH grants a collaborator an exclusive option to elect an exclusive or non-exclusive commercialization license.   On June 14, 2017, the Company executed Amendment No. 1 to the M-CRADA, pursuant to which the Company agreed to provide funding in the amount of $100,000 to the National Cancer Institute for use in acquiring technical, statistical and administrative support for research activities. The $100,000 amount was scheduled to be paid in two equal installments of $50,000, the first installment of which was paid, as scheduled, on July 9, 2017, and was charged to research and development costs in the consolidated statement of operations on such date. The second installment of $50,000 was scheduled to be paid on the June 14, 2018 anniversary date of the amendment and was accreted ratably through such date and included in research and development contract liabilities in the Company’s consolidated balance sheet. Pursuant to revised and updated collaboration plans, on November 3, 2018, the NINDS and the Company agreed to a cancellation of the second installment payment of $50,000. Accordingly, the previously accreted charge of $50,000, of which $25,000 was recorded during the six months ended June 30, 2018, was reversed during the fourth quarter of the year ended December 31, 2018. During the three months ended March 31, 2018, $12,500, was included in research and development costs in the consolidated statement of operations.   On December 24, 2013, the Company entered into an agreement with NDA Consulting Corp. (“NDA”) for consultation and advice in the field of oncology research and drug development. As part of the agreement, NDA also agreed to cause its president, Dr. Daniel D. Von Hoff, M.D., to become a member of the Company’s Scientific Advisory Committee. The term of the agreement was for one year and provided for a quarterly cash fee of $4,000. In 2014, 2015, 2016, 2017 and 2018, the agreement was automatically renewed on its anniversary date for an additional one-year term. Consulting and advisory fees charged to operations pursuant to this agreement were $4,000 during the three months ended March 31, 2019 and 2018.   Effective September 14, 2015, the Company entered into a Collaboration Agreement with BioPharmaWorks, pursuant to which the Company engaged BioPharmaWorks to perform certain services for the Company. Those services include, among other things: (a) assisting the Company to (i) commercialize its products and strengthen its patent portfolio, (ii) identify large pharmaceutical companies with potential interest in the Company’s product pipeline, and (iii) prepare and deliver presentations concerning the Company’s products; (b) at the request of the Board of Directors, serving as backup management for up to three months should the Company’s Chief Executive Officer and scientific leader be temporarily unable to carry out his duties; (c) being available for consultation in drug discovery and development; and (d) identifying providers and overseeing tasks relating to clinical use and commercialization of new compounds.   BioPharmaWorks was founded in 2015 by former Pfizer scientists with extensive multi-disciplinary research and development and drug development experience. The Collaboration Agreement was for an initial term of two years and automatically renews for subsequent annual periods unless terminated by a party not less than 60 days prior to the expiration of the applicable period. In connection with the Collaboration Agreement, the Company agreed to pay BioPharmaWorks a monthly fee of $10,000, subject to the right of the Company to pay a negotiated hourly rate in lieu of the monthly payment and agreed to issue to BioPharmaWorks certain equity-based compensation. In November 2016, it was mutually agreed to suspend services and payments under the Collaboration Agreement, without extending its term, for the period from November 1, 2016 through March 31, 2017. The Collaboration Agreement resumed as scheduled on April 1, 2017 and was automatically renewed for additional one-year periods on September 13, 2017 and 2018, respectively. In April 2018, it was again mutually agreed to suspend services and payments under the Collaboration Agreement, without extending its term, for the period from February 1, 2018 through the September 13, 2019 anniversary date. In February 2019, the Company and BioPharmaWorks subsequently agreed to resume the Collaboration Agreement effective March 1, 2019. The Company recorded charges to operations pursuant to this Collaboration Agreement of $10,000 and $10,000, which were included in research and development costs in the consolidated statement of operations, during the three months ended March 31, 2019 and 2018, respectively.    On March 22, 2018, the Company entered into a Patent Assignment and Exploitation Agreement (the “Agreement”) with INSERM TRANSFERT SA, acting as delegatee of the French National Institute of Health and Medical Research (“INSERM”), for the assignment to the Company of INSERM’S interest in United States Patent No. 9,833,450 entitled “Oxabicyloheptanes and Oxabicycloheptenes for the Treatment of Depressive and Stress Disorders”, which was filed with the United States Patent and Trademark Office in the name of INSERM and the Company as co-owners on February 19, 2015 and granted on May 12, 2017, and related patent applications and filings. INSERM is a French public institution dedicated to research in the field of health and medicine that had previously entered into a Material Transfer Agreement (“MTA”) with the Company to allow INSERM to conduct research on the Company’s proprietary compound LB-100 and/or its analogs for the treatment of depressive or stress disorders in humans. Pursuant to the Agreement, the Company has agreed to make certain milestone payments to INSERM aggregating up to $1,750,000 upon achievement of development milestones and up to $6,500,000 upon achievement of commercial milestones. The Company also agreed to pay INSERM certain commercial royalties on net sales of products attributed to the Agreement. The Company’s current plan is to complete the validation process to evaluate LB-100 for the treatment of depressive or stress disorders in humans within three years; however, the exploitation of this patent for the treatment of depressive and stress disorders in humans will require substantial additional capital and/or a joint venture or other type of business arrangement with a pharmaceutical company with substantially greater capital and business resources than those available to the Company. As there can be no assurances that the Company will be able to obtain the capital or business resources necessary to focus on the exploitation of this patent, it is uncertain when the Company may reach any of the development or commercialization milestones under the Agreement, if at all.   Effective April 2, 2018, the Company entered into a consulting agreement for a term of two years with Liberi Life Sciences Consultancy BV, located in The Netherlands, for consulting and advisory services with respect to sales and licensing, as well as the procurement of investors in China, Japan and South Korea (the “Consulting Agreement”). The Consulting Agreement provided for the payment of a fixed, one-time retainer of EURO 15,000 (US $18,348), which was paid on April 5, 2018, and 2.5% of the net payments received by the Company from sales of products or licensing activities arising directly and exclusively from leads generated by the advisor during the term of the Consulting Agreement, and any investors introduced to the Company by the advisor that results in an investment in the Company during the term of the Consulting Agreement. The Company recorded the payment of the retainer as a prepaid expense in the Company’s consolidated balance sheet. The Company is amortizing the retainer payment over the two-year life of the Consulting Agreement, as a result of which the Company recorded a charge to operations of $2,294 during the three months ended March 31, 2019. At March 31, 2019, the unamortized balance of the retainer payment was $9,174, all of which was classified as a current asset in the Company’s consolidated balance sheet at such date. At December 31, 2018, the unamortized balance of the retainer payment was $11,468, of which $9,175 was classified as a current asset and $2,293 was classified as a non-current asset in the Company’s consolidated balance sheet at such date.   Effective August 20, 2018 (the “Effective Date”), the Company and the Moffitt Cancer Center and Research Institute Hospital Inc., Tampa, Florida (“Moffitt”) entered into an Exclusive License Agreement (the “License Agreement”). Pursuant to the License Agreement, Moffitt granted the Company an exclusive license under certain patents owned by Moffitt (the “Licensed Patents”) relating to the treatment of MDS and a non-exclusive license under inventions, concepts, processes, information, data, know-how, research results, clinical data, and the like (other than the Licensed Patents) necessary or useful for the practice of any claim under the Licensed Patents or the use, development, manufacture or sale of any product for the treatment of MDS which would otherwise infringe a valid claim under the Licensed Patents. The Company is obligated to pay Moffitt a non-refundable license issue fee of $25,000 after the first patient is entered into a Phase 1b/2 clinical trial to be managed and conducted by Moffitt. This clinical trial began during April 2019. The Company is also obligated to pay Moffitt an annual license maintenance fee of $25,000 commencing on the first anniversary of the Effective Date and every anniversary thereafter until the Company commences payment of minimum royalty payments. The Company has also agreed to pay non-refundable milestone payments to Moffitt, which cannot be credited against earned royalties payable by the Company, based on reaching various clinical and commercial milestones aggregating $1,897,000, subject to reduction by 40% under certain circumstances relating to the status of Valid Claims, as such term is defined in the License Agreement. During the three months ended March 31, 2019, the Company recorded a charge to operations of $15,274 in connection with these license agreements.   The Company will be obligated to pay Moffitt earned royalties of 4% on worldwide cumulative net sales of royalty-bearing products, subject to reduction to 2% under certain circumstances, on a quarterly basis, with a minimum royalty payment of $50,000 in the first four years after sales commence, and $100,000 in year five and each year thereafter, subject to reduction by 40% under certain circumstances relating to the status of Valid Claims, as such term is defined in the License Agreement. The Company’s obligation to pay earned royalties under the License Agreement commences on the date of the first sale of a royalty-bearing product, and shall automatically expire on a country-by-country basis on the date on which the last valid claim of the Licensed Patents expires, lapses or is declared invalid, and the obligation to pay any earned royalties under the License Agreement shall terminate on the date on which the last valid claim of the Licensed Patents expires, lapses, or is declared to be invalid in all countries.    Effective August 20, 2018, the Company and Moffitt also entered into a Clinical Trial Research Agreement (the “Clinical Trial Research Agreement”) effective for a term of five years, unless terminated earlier by the Company pursuant to 30 days written notice. Pursuant to the Clinical Trial Research Agreement, Moffitt will conduct and manage a Phase 1b/2 clinical trial to evaluate the therapeutic benefit of the Company’s lead anti-cancer clinical compound LB-100 to be administered intravenously in patients with low or intermediate-1 risk MDS.   In early November 2018, the Company received approval from the FDA for its Investigational New Drug (IND) Application to conduct a Phase 1b/2 clinical trial to evaluate the therapeutic benefit of the Company’s lead clinical compound LB-100 in patients with low and intermediate-1 risk myelodysplastic syndrome (MDS) who have failed or are intolerant of standard treatment. This clinical trial began during April 2019 and is expected to complete patient accrual over a period of two years, with final analysis and reporting expected within three years.   On September 12, 2018, the Company finalized a work order agreement with Theradex to monitor the Phase 1b/2 clinical trial being conducted by Moffitt that began during April 2019. The clinical trial will be managed and conducted by Moffitt to evaluate the therapeutic benefit of the Company’s lead anti-cancer clinical compound LB-100 administered intravenously in patients with low or intermediate-1 risk MDS. This work order agreement became operational in August 2018 and is estimated to be completed by December 2021. Costs under this work order agreement are estimated to be approximately $954,000. During the three months ended March 31, 2019, the Company paid Theradex $32,964 pursuant to this work order. As of March 31, 2019, total costs of $44,870 have been incurred pursuant to this work order agreement.

0001335105

0.0001

100000000

67045814

3893604

4273012

1305748

808038

1. Organization and Basis of Presentation   The condensed consolidated financial statements of Lixte Biotechnology Holdings, Inc., a Delaware corporation (“Holdings”), including its wholly-owned Delaware subsidiary, Lixte Biotechnology, Inc. (“Lixte”) (collectively, the “Company”), at March 31, 2019, and for the three months ended March 31, 2019 and 2018, are unaudited. In the opinion of management of the Company, all adjustments, including normal recurring accruals, have been made that are necessary to present fairly the financial position of the Company as of March 31, 2019, and the results of its operations for the three months ended March 31, 2019 and 2018, and its cash flows for the three months ended March 31, 2019 and 2018. Operating results for the interim periods presented are not necessarily indicative of the results to be expected for a full fiscal year. The consolidated balance sheet at December 31, 2018 has been derived from the Company’s audited consolidated financial statements at such date.   The condensed consolidated financial statements and related notes have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been omitted pursuant to such rules and regulations. These condensed consolidated financial statements should be read in conjunction with the financial statements and other information included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018, as filed with the SEC.

3. Summary of Significant Accounting Policies   Principles of Consolidation   The accompanying condensed consolidated financial statements of the Company have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) and include the financial statements of Holdings and its wholly-owned subsidiary, Lixte. Intercompany balances and transactions have been eliminated in consolidation.   Use of Estimates   The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable in relation to the financial statements taken as a whole under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Management regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available information, changes in facts and circumstances, historical experience and reasonable assumptions. After such evaluations, if deemed appropriate, those estimates are adjusted accordingly. Actual results could differ from those estimates. Significant estimates include those related to assumptions used in accruals for potential liabilities, valuing equity instruments issued for services, and the realization of deferred tax assets.   Cash and Cash Equivalents   Cash and cash equivalents include short-term federally insured certificates of deposit. The Company maintains its cash balances with financial institutions in federally-insured accounts. The Company may periodically have cash balances in banks in excess of FDIC insurance limits. The Company maintains its accounts with financial institutions with high credit ratings. The Company has not experienced any losses to date resulting from this practice.    Research and Development   Research and development costs consist primarily of fees paid to consultants and outside service providers, and other expenses relating to the acquisition, design, development and testing of the Company’s compounds and product candidates.   Research and development costs are charged to operations ratably over the life of the underlying contracts, unless the achievement of milestones, the completion of contracted work, or other information indicates that a different expensing schedule is more appropriate.   Obligations incurred with respect to mandatory scheduled payments under research agreements without milestone provisions are recognized ratably over the appropriate period, as specified in the agreement, and are recorded as liabilities in the Company’s consolidated balance sheet, with a corresponding charge to research and development costs in the Company’s consolidated statement of operations.   On January 10, 2010, the Company retained Theradex Systems, Inc. (“Theradex”) under a Master Agreement to provide technical and advisory services to the Company with respect to clinical trial matters involving the U.S. Food and Drug Administration (“FDA”). Theradex is an international contract research organization (“CRO”) that provides technical and advisory services with respect to clinical research and development of pharmaceutical compounds under the rules and regulations of the FDA. On September 21, 2012, the Company entered into a work order agreement with Theradex to manage and administer the Company’s Phase 1 clinical trial of LB-100. This Phase 1 clinical trial had been substantially completed at December 31, 2017.   On September 12, 2018, the Company finalized a work order agreement with Theradex to monitor a Phase 1b/2 clinical trial that was approved by the FDA in early November 2018 to evaluate the therapeutic benefit of LB-100 in MDS. This clinical trial began during April 2019 and is expected to complete patient accrual over a period of two years, with final analysis and reporting expected within three years. The clinical trial will be managed and conducted by the Moffitt Cancer Center and Research Institute Hospital Inc., Tampa, Florida, to evaluate the therapeutic benefit of the Company’s lead anti-cancer clinical compound LB-100 administered intravenously in patients with low or intermediate-1 risk myelodysplastic syndrome (MDS). This work order agreement became operational in August 2018 and is estimated to be completed by December 2021. Costs under this work order agreement are estimated to be approximately $954,000, with such payments expected to be divided approximately 94% to Theradex for services and approximately 6% for payments for pass-through costs. The costs of the upcoming Phase 1b/2 clinical trial to be paid to or through Theradex will be recorded and charged to operations based on the periodic documentation provided by the CRO. During the three months ended March 31, 2019, the Company paid Theradex $32,964 pursuant to this work order. As of March 31, 2019, total costs of $44,870 have been incurred pursuant to this work order agreement.   In addition to the costs associated with the previously described work order agreements with Theradex with respect to the Company’s clinical trials, the Company has also from time to time engaged Theradex to provide other technical and advisory services.   Payments made pursuant to research and development contracts are initially recorded as advances on research and development contract services in the Company’s consolidated balance sheet and then charged to research and development costs in the Company’s consolidated statement of operations as those contract services are performed. Expenses incurred under research and development contracts in excess of amounts advanced are recorded as research and development contract liabilities in the Company’s consolidated balance sheet, with a corresponding charge to research and development costs in the Company’s consolidated statement of operations. The Company reviews the status of its research and development contracts on a quarterly basis.   Patent and Licensing Costs   Due to the significant uncertainty associated with the successful development of one or more commercially viable products based on the Company’s research efforts and related patent applications, all patent-related legal and filing fees and licensing-related legal fees are charged to operations as incurred. Patent and licensing costs were $190,773 and $217,659 for the three months ended March 31, 2019 and 2018, respectively. Patent and licensing costs are included in general and administrative costs in the Company’s consolidated statements of operations.   Concentration of Risk   The Company periodically contracts with directors, including companies controlled by or associated with directors, to provide consulting services related to the Company’s research and development and clinical trial activities. Agreements for these services can be for a specific time period (typically one year) or for a specific project or task and can include both cash and non-cash compensation. The only such contracts that represent 10% or more of general and administrative or research and development costs are described below.    As discussed above at “Research and Development”, the Company had retained Theradex to provide technical and advisory services to the Company with respect to clinical trial matters involving the FDA, including monitoring a Phase 1b/2 clinical trial that was approved by the FDA in early November 2018 to evaluate the therapeutic benefit of LB-100 in MDS. This clinical trial began during April 2019 and is expected to complete patient accrual over a period of two years, with final analysis and reporting expected within three years.   Costs incurred pursuant to the agreements with Theradex are included in research and development costs in the Company’s consolidated statements of operations.   Income Taxes   The Company accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly, the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and the tax basis of assets and liabilities.   The Company has elected to deduct research and development costs on a current basis for federal income tax purposes. For federal tax purposes, start-up and organization costs were deferred until January 1, 2008 at which time the Company began to amortize such costs over a 180-month period.   The Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. In the event the Company was to determine that it would be able to realize its deferred tax assets in the future in excess of its recorded amount, an adjustment to the deferred tax assets would be credited to operations in the period such determination was made. Likewise, should the Company determine that it would not be able to realize all or part of its deferred tax assets in the future, an adjustment to the deferred tax assets would be charged to operations in the period such determination was made.   The Company is subject to U.S. federal income taxes and income taxes of various state tax jurisdictions. As the Company’s net operating losses have yet to be utilized, all previous tax years remain open to examination by Federal authorities and other jurisdictions in which the Company currently operates or has operated in the past. The Company had no unrecognized tax benefits as of March 31, 2019 and December 31, 2018 and does not anticipate any material amount of unrecognized tax benefits within the next 12 months.   The Company accounts for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by GAAP. The tax effects of a position are recognized only if it is “more-likely-than-not” to be sustained by the taxing authority as of the reporting date. If the tax position is not considered “more-likely-than-not” to be sustained, then no benefits of the position are recognized. As of March 31, 2019, the Company had not recorded any liability for uncertain tax positions. In subsequent periods, any interest and penalties related to uncertain tax positions will be recognized as a component of income tax expense.   Stock-Based Compensation   The Company periodically issues common stock and stock options to officers, directors, Scientific Advisory Committee members and consultants for services rendered. Options vest and expire according to terms established at the issuance date of each grant.   The Company accounts for stock-based payments to officers and directors by measuring the cost of services received in exchange for equity awards utilizing the grant date fair value of the awards, with the cost recognized as compensation expense on the straight-line basis in the Company’s financial statements over the vesting period of the awards. The Company accounts for stock-based payments to Scientific Advisory Committee members and consultants by determining the value of the stock compensation based upon the measurement date at either (a) the date at which a performance commitment is reached or (b) at the date at which the necessary performance to earn the equity instruments is complete.   Stock grants, which are generally time vested, are measured at the grant date fair value and charged to operations ratably over the vesting period.    Stock options granted to members of the Company’s Scientific Advisory Committee and to outside consultants are revalued each reporting period to determine the amount to be recorded as an expense in the respective period. As the stock options vest, they are valued on each vesting date and an adjustment is recorded for the difference between the value already recorded and the value on the date of vesting.   The fair value of common stock issued as stock-based compensation is determined by reference to the closing price of the Company’s common stock on the date of issuance. The fair value of stock options granted as stock-based compensation is determined utilizing the Black-Scholes option-pricing model, and is affected by several variables, the most significant of which are the life of the equity award, the exercise price of the stock option as compared to the fair market value of the common stock on the grant date, and the estimated volatility of the common stock over the term of the equity award. Estimated volatility is based on the historical volatility of the Company’s common stock. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant. The fair market value of common stock is determined by reference to the quoted market price of the Company’s common stock.   The Company recognizes the fair value of stock-based compensation awards in general and administrative costs and in research and development costs, as appropriate, in the Company’s consolidated statements of operations. The Company issues new shares of common stock to satisfy stock option exercises.   Earnings (Loss) Per Share   The Company’s computation of earnings (loss) per share (“EPS”) includes basic and diluted EPS. Basic EPS is measured as the income (loss) attributable to common stockholders divided by the weighted average common shares outstanding for the period. Diluted EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares (e.g., preferred shares, warrants and stock options) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS.   Loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the respective periods. Basic and diluted loss per common share is the same for all periods presented because all preferred shares, warrants and stock options outstanding are anti-dilutive.   At March 31, 2019 and 2018, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive.   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">March 31,</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2019</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2018</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 63%; line-height: 107%">Series A Convertible Preferred Stock</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 15%; text-align: right; line-height: 107%">4,375,000</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 15%; text-align: right; line-height: 107%">4,375,000</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Common stock warrants</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">9,000,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">—</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Common stock options, including options issued in the form of warrants</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">7,750,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">7,470,000</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Total</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">21,125,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">11,845,000</td> <td style="line-height: 107%"> </td></tr> </table>   Fair Value of Financial Instruments   The authoritative guidance with respect to fair value established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels and requires that assets and liabilities carried at fair value be classified and disclosed in one of three categories, as presented below. Disclosure as to transfers in and out of Levels 1 and 2, and activity in Level 3 fair value measurements, is also required.   Level 1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities and exchange-based derivatives.   Level 2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities, non-exchange-based derivatives, mutual funds, and fair-value hedges.   Level 3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently-traded non-exchange-based derivatives and commingled investment funds and are measured using present value pricing models.   The Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company performs an analysis of the assets and liabilities at each reporting period end.   The carrying value of financial instruments (consisting of cash and cash equivalents, and accounts payable and accrued expenses) is considered to be representative of their respective fair values due to the short-term nature of those instruments.   Recent Accounting Pronouncements   In June 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update 2018-07, Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting (“ASU 2018-07”). ASU 2018-07 expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. ASU 2018-07 also clarifies that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Revenue from Contracts with Customers (Topic 606). ASU 2018-07 was effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company adopted the provisions of ASU 2018-07 in the quarter beginning January 1, 2019. The adoption of ASU 2018-07 did not have any impact on the Company’s financial statement presentation or disclosures.   Management does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the Company’s financial statement presentation or disclosures.

4. Stockholders’ Equity   Preferred Stock   The Company has authorized a total of 10,000,000 shares of preferred stock, par value $0.0001 per share. On March 17, 2015, the Company filed a Certificate of Designations, Preferences, Rights and Limitations (the “Certificate of Designations”) of its Series A Convertible Preferred Stock with the Delaware Secretary of State to amend the Company’s certificate of incorporation. The Company designated 175,000 shares as Series A Convertible Preferred Stock, which are non-voting and are not subject to increase without the written consent of a majority of the holders of the Series A Convertible Preferred Stock or as otherwise set forth in the Certificate of Designations. The holders of each tranche of 175,000 shares of the Series A Convertible Preferred Stock are entitled to receive a per share dividend equal to 1% of the annual net revenue of the Company divided by 175,000, until converted or redeemed.   Effective January 28, 2016, the Series A Convertible Preferred Stock Certificate of Designations was amended to increase the authorized shares of Series A Convertible Preferred Stock from 175,000 shares to 350,000 shares. Accordingly, as of March 31, 2019, 9,650,000 shares of preferred stock were undesignated and may be issued with such rights and powers as the Board of Directors may designate.   Each share of Series A Convertible Preferred Stock may be converted, at the option of the holder, into 12.5 shares of common stock (subject to customary anti-dilution provisions) and the Series A Convertible Preferred Stock is subject to mandatory conversion at the conversion rate in the event of a merger or sale transaction resulting in gross proceeds to the Company of at least $21,875,000. The Series A Convertible Preferred Stock has a liquidation preference based on its assumed conversion into shares of common stock. The Series A Convertible Preferred Stock does not have a cash liquidation preference.   If fully converted, the 350,000 outstanding shares of Series A Convertible Preferred Stock would convert into 4,375,000 shares of common stock at March 31, 2019. The Company has the right to redeem the Series A Convertible Preferred Stock up to the fifth anniversary of the respective closing dates at a price per share equal to $50.00. The Series A Convertible Preferred Stock has no right to cash, except for the payment of the aforementioned dividend based on the generation of revenues by the Company and does not have any registration rights.   Based on the attributes of the Series A Convertible Preferred Stock described above, the Company determined to account for the Series A Convertible Preferred Stock as a permanent component of stockholders’ equity.   Common Stock   The Company is authorized to issue up to 100,000,000 shares of common stock (par value $0.0001). As of March 31, 2019 and December 31, 2018, the Company had 67,045,814 shares of common stock issued and outstanding.   Common Stock Warrants   A summary of common stock warrant activity, including warrants to purchase common stock that were issued in conjunction with the Company’s private placements, during the three months ended March 31, 2019 is presented below.   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Number of Shares</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Weighted Average Exercise Price</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Weighted Average Remaining Contractual Life (in Years)</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 46%; line-height: 107%">Warrants outstanding at December 31, 2018</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 12%; text-align: right; line-height: 107%">9,000,000</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 12%; text-align: right; line-height: 107%">1.000</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 21%; text-align: right; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Issued</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">—</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">—</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Exercised</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">—</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">—</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Expired</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">—</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">—</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Warrants outstanding at March 31, 2019</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">9,000,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">1.000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">3.67</td> <td style="line-height: 107%"> </td></tr> </table>   At March 31, 2019, all outstanding warrants are exercisable at $1.000 per common share.   Based on a fair market value of $0.90 per share on March 31, 2019, there were no exercisable but unexercised in-the-money common stock warrants on that date. Accordingly, there was no intrinsic value attributed to exercisable but unexercised common stock warrants at March 31, 2019.   Information with respect to the issuance of common stock in connection with various stock-based compensation arrangements is provided at Note 6.

5. Related Party Transactions   The Company’s Chairman and major stockholder, Dr. John Kovach, was paid a salary of $15,000 for the three months ended March 31, 2019 and 2018, which amounts are included in general and administrative costs in the Company’s consolidated statements of operations. Beginning in late February 2017, Dr. Kovach began devoting 100% of his time to the Company’s business activities.   The Company’s principal office facilities are being provided without charge by Dr. Kovach. Such costs were not material to the Company’s consolidated financial statements and, accordingly, have not been reflected therein.   On September 12, 2007, the Company entered into a consulting agreement with Gil Schwartzberg for Mr. Schwartzberg to provide financial advisory and consulting services to the Company with respect to financing matters, capital structure and strategic development, and to assist management in communications with investors and shareholders. Mr. Schwartzberg is currently a significant stockholder of the Company and continues to be a consultant to the Company. Consideration under this consulting agreement, including subsequent extensions, has been paid exclusively in the form of stock options. On January 28, 2014, the Company entered into a second amendment to its consulting agreement with Mr. Schwartzberg to extend it to January 28, 2019. In conjunction with such amendment, the Company granted Mr. Schwartzberg stock options to purchase an additional 4,000,000 shares of common stock, exercisable at $0.50 per share for a period of the earlier of five years from the grant date or the termination of the consulting agreement, with one-half of the stock options (2,000,000 shares) vested immediately and one-half of the stock options (2,000,000 shares) vested on January 28, 2015. Stock-based compensation expense with respect to the grant of the stock options to purchase the 4,000,000 shares of common stock was previously charged to general and administrative costs in the consolidated statement of operations over the vesting period. On August 2, 2018, with the approval of the Board of Directors, the Company entered into a third amendment to its consulting agreement with Mr. Schwartzberg to extend it to January 28, 2024. In conjunction with such amendment, the Company extended the expiration date of the fully-vested stock options for 4,000,000 shares of common stock previously granted to Mr. Schwartzberg, from January 28, 2019 to January 28, 2024. The fair value of the extension of these vested stock options, as calculated pursuant to the Black-Scholes option-pricing model, was measured for accounting purposes as the difference in the fair value of the stock options immediately before and immediately after the extension date, and was charged to general and administrative costs in the consolidated statement of operations on August 2, 2018.    Legal and consulting fees charged to operations for services rendered by the Eric Forman Law Office were $12,000 for the three months ended March 31, 2019 and 2018, respectively. Eric J. Forman is the son-in-law of Gil Schwartzberg, a significant stockholder of and consultant to the Company, and is the son of Dr. Stephen J. Forman, who was elected to the Company’s Board of Directors on May 13, 2016. Julie Forman, the wife of Eric Forman and the daughter of Gil Schwartzberg, is Vice President of Morgan Stanley Wealth Management, where the Company maintains a banking relationship.   Stock-based compensation arrangements involving members of the Company’s Board of Directors and affiliates are described at Note 6. Total stock-based compensation expense relating to directors, officers, affiliates and related parties was $12,936 and $0 for the three months ended March 31, 2019 and 2018, respectively.

6. Stock-Based Compensation   The Company issues common stock and stock options as incentive compensation to directors and as compensation for the services of independent contractors and consultants of the Company.   On June 20, 2007, the Board of Directors of the Company approved the 2007 Stock Compensation Plan (the “2007 Plan”), which provides for the granting of awards, consisting of stock options, stock appreciation rights, performance shares, or restricted shares of common stock, to employees and independent contractors, for up to 2,500,000 shares of the Company’s common stock, under terms and conditions as determined by the Company’s Board of Directors. The 2007 Plan terminated on June 19, 2017. As of March 31, 2019, unexpired stock options for 1,250,000 shares were issued and outstanding under the 2007 Plan.   The fair value of each stock option awarded is calculated on the date of grant and subsequent measurement dates using the Black-Scholes option-pricing model. The expected dividend yield assumption is based on the Company’s expectation of dividend payouts. The expected volatilities are based on historical volatility of the Company’s stock. The risk-free interest rate is based on the U.S. treasury yield curve in effect as of the grant date. The expected life of the stock options is the average of the vesting term and the full contractual term of the stock options.   There were no stock options requiring an assessment of value during the three months ended March 31, 2019 and 2018.   Effective August 4, 2018, in conjunction with their appointments as directors of the Company, the Company granted to Dr. Winson Sze Chun Ho and Dr. Yun Yen stock options for each person to purchase an aggregate of 200,000 shares of the Company’s common stock, exercisable for a period of five years from the vesting date at $0.28 per share, which was the approximate fair market value of the Company’s common stock on such date. One-half of such stock options (100,000 shares each) vested on August 4, 2018 and the remaining one-half of such stock options (100,000 shares each) will vest on August 4, 2019. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $104,920 ($0.2623 per share), of which $52,460 was attributable to the stock options fully-vested on August 4, 2018 and was therefore was charged to operations on that date. The remaining unvested portion of the fair value of the stock options will be charged to operations ratably from August 4, 2018 through August 4, 2019. During the three months ended March 31, 2019, the Company recorded a charge to operations of $12,936 with respect to these stock options.   Total stock-based compensation expense was $12,936 and $0 for the three months ended March 31, 2019 and 2018, respectively.    A summary of stock option activity, including options issued in the form of warrants, during the three months ended March 31, 2019 is presented below.   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Number of Shares</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Weighted Average Exercise Price</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Weighted Average Remaining Contractual Life (in Years)</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 50%; line-height: 107%">Stock options outstanding at December 31, 2018</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 14%; text-align: right; line-height: 107%">7,750,000</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 13%; text-align: right; line-height: 107%">0.583</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 13%; text-align: right; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Granted</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">—</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">—</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Exercised</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">—</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">—</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Expired</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">—</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">—</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Stock options outstanding at March 31, 2019</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">7,750,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">0.538</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">3.43</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Stock options exercisable at March 31, 2019</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">7,550,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">0.545</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">3.41</td> <td style="line-height: 107%"> </td></tr> </table>   Total deferred compensation expense for the outstanding value of unvested stock options was approximately $18,000 at March 31, 2019, which will be recognized subsequent to March 31, 2018 over a weighted-average period of approximately four months.   The exercise prices of common stock options outstanding and exercisable, including options issued in the form of warrants, are as follows at March 31, 2019:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Exercise  Prices</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Options  Outstanding (Shares)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Options Exercisable (Shares)</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 34%; text-align: right; line-height: 107%">0.120</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 29%; text-align: right; line-height: 107%">450,000</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 29%; text-align: right; line-height: 107%">450,000</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.150</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">300,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">300,000</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.160</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">200,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">200,000</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.200</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">500,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">500,000</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.250</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">500,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">500,000</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.280</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">400,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">200,000</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.500</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">4,400,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">4,400,000</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">1.000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">500,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">500,000</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">2.000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">500,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">500,000</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">7,750,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">7,550,000</td> <td style="line-height: 107%"> </td></tr> </table>   The intrinsic value of exercisable but unexercised in-the-money stock options at March 31, 2019 was approximately $3,283,000, based on a fair market value of $0.90 per share on March 31, 2019.   Outstanding options to acquire 200,000 shares of the Company’s common stock had not vested at March 31, 2019.   The Company expects to satisfy such stock obligations through the issuance of authorized but unissued shares of common stock.

Principles of Consolidation   The accompanying condensed consolidated financial statements of the Company have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) and include the financial statements of Holdings and its wholly-owned subsidiary, Lixte. Intercompany balances and transactions have been eliminated in consolidation.

Use of Estimates   The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable in relation to the financial statements taken as a whole under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Management regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available information, changes in facts and circumstances, historical experience and reasonable assumptions. After such evaluations, if deemed appropriate, those estimates are adjusted accordingly. Actual results could differ from those estimates. Significant estimates include those related to assumptions used in accruals for potential liabilities, valuing equity instruments issued for services, and the realization of deferred tax assets.

Cash and Cash Equivalents   Cash and cash equivalents include short-term federally insured certificates of deposit. The Company maintains its cash balances with financial institutions in federally-insured accounts. The Company may periodically have cash balances in banks in excess of FDIC insurance limits. The Company maintains its accounts with financial institutions with high credit ratings. The Company has not experienced any losses to date resulting from this practice.

Research and Development   Research and development costs consist primarily of fees paid to consultants and outside service providers, and other expenses relating to the acquisition, design, development and testing of the Company’s compounds and product candidates.   Research and development costs are charged to operations ratably over the life of the underlying contracts, unless the achievement of milestones, the completion of contracted work, or other information indicates that a different expensing schedule is more appropriate.   Obligations incurred with respect to mandatory scheduled payments under research agreements without milestone provisions are recognized ratably over the appropriate period, as specified in the agreement, and are recorded as liabilities in the Company’s consolidated balance sheet, with a corresponding charge to research and development costs in the Company’s consolidated statement of operations.   On January 10, 2010, the Company retained Theradex Systems, Inc. (“Theradex”) under a Master Agreement to provide technical and advisory services to the Company with respect to clinical trial matters involving the U.S. Food and Drug Administration (“FDA”). Theradex is an international contract research organization (“CRO”) that provides technical and advisory services with respect to clinical research and development of pharmaceutical compounds under the rules and regulations of the FDA. On September 21, 2012, the Company entered into a work order agreement with Theradex to manage and administer the Company’s Phase 1 clinical trial of LB-100. This Phase 1 clinical trial had been substantially completed at December 31, 2017.   On September 12, 2018, the Company finalized a work order agreement with Theradex to monitor a Phase 1b/2 clinical trial that was approved by the FDA in early November 2018 to evaluate the therapeutic benefit of LB-100 in MDS. This clinical trial began during April 2019 and is expected to complete patient accrual over a period of two years, with final analysis and reporting expected within three years. The clinical trial will be managed and conducted by the Moffitt Cancer Center and Research Institute Hospital Inc., Tampa, Florida, to evaluate the therapeutic benefit of the Company’s lead anti-cancer clinical compound LB-100 administered intravenously in patients with low or intermediate-1 risk myelodysplastic syndrome (MDS). This work order agreement became operational in August 2018 and is estimated to be completed by December 2021. Costs under this work order agreement are estimated to be approximately $954,000, with such payments expected to be divided approximately 94% to Theradex for services and approximately 6% for payments for pass-through costs. The costs of the upcoming Phase 1b/2 clinical trial to be paid to or through Theradex will be recorded and charged to operations based on the periodic documentation provided by the CRO. During the three months ended March 31, 2019, the Company paid Theradex $32,964 pursuant to this work order. As of March 31, 2019, total costs of $44,870 have been incurred pursuant to this work order agreement.   In addition to the costs associated with the previously described work order agreements with Theradex with respect to the Company’s clinical trials, the Company has also from time to time engaged Theradex to provide other technical and advisory services.   Payments made pursuant to research and development contracts are initially recorded as advances on research and development contract services in the Company’s consolidated balance sheet and then charged to research and development costs in the Company’s consolidated statement of operations as those contract services are performed. Expenses incurred under research and development contracts in excess of amounts advanced are recorded as research and development contract liabilities in the Company’s consolidated balance sheet, with a corresponding charge to research and development costs in the Company’s consolidated statement of operations. The Company reviews the status of its research and development contracts on a quarterly basis.

Patent and Licensing Costs   Due to the significant uncertainty associated with the successful development of one or more commercially viable products based on the Company’s research efforts and related patent applications, all patent-related legal and filing fees and licensing-related legal fees are charged to operations as incurred. Patent and licensing costs were $190,773 and $217,659 for the three months ended March 31, 2019 and 2018, respectively. Patent and licensing costs are included in general and administrative costs in the Company’s consolidated statements of operations.

Concentration of Risk   The Company periodically contracts with directors, including companies controlled by or associated with directors, to provide consulting services related to the Company’s research and development and clinical trial activities. Agreements for these services can be for a specific time period (typically one year) or for a specific project or task and can include both cash and non-cash compensation. The only such contracts that represent 10% or more of general and administrative or research and development costs are described below.    As discussed above at “Research and Development”, the Company had retained Theradex to provide technical and advisory services to the Company with respect to clinical trial matters involving the FDA, including monitoring a Phase 1b/2 clinical trial that was approved by the FDA in early November 2018 to evaluate the therapeutic benefit of LB-100 in MDS. This clinical trial began during April 2019 and is expected to complete patient accrual over a period of two years, with final analysis and reporting expected within three years.   Costs incurred pursuant to the agreements with Theradex are included in research and development costs in the Company’s consolidated statements of operations.

Income Taxes   The Company accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly, the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and the tax basis of assets and liabilities.   The Company has elected to deduct research and development costs on a current basis for federal income tax purposes. For federal tax purposes, start-up and organization costs were deferred until January 1, 2008 at which time the Company began to amortize such costs over a 180-month period.   The Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. In the event the Company was to determine that it would be able to realize its deferred tax assets in the future in excess of its recorded amount, an adjustment to the deferred tax assets would be credited to operations in the period such determination was made. Likewise, should the Company determine that it would not be able to realize all or part of its deferred tax assets in the future, an adjustment to the deferred tax assets would be charged to operations in the period such determination was made.   The Company is subject to U.S. federal income taxes and income taxes of various state tax jurisdictions. As the Company’s net operating losses have yet to be utilized, all previous tax years remain open to examination by Federal authorities and other jurisdictions in which the Company currently operates or has operated in the past. The Company had no unrecognized tax benefits as of March 31, 2019 and December 31, 2018 and does not anticipate any material amount of unrecognized tax benefits within the next 12 months.   The Company accounts for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by GAAP. The tax effects of a position are recognized only if it is “more-likely-than-not” to be sustained by the taxing authority as of the reporting date. If the tax position is not considered “more-likely-than-not” to be sustained, then no benefits of the position are recognized. As of March 31, 2019, the Company had not recorded any liability for uncertain tax positions. In subsequent periods, any interest and penalties related to uncertain tax positions will be recognized as a component of income tax expense.

Stock-Based Compensation   The Company periodically issues common stock and stock options to officers, directors, Scientific Advisory Committee members and consultants for services rendered. Options vest and expire according to terms established at the issuance date of each grant.   The Company accounts for stock-based payments to officers and directors by measuring the cost of services received in exchange for equity awards utilizing the grant date fair value of the awards, with the cost recognized as compensation expense on the straight-line basis in the Company’s financial statements over the vesting period of the awards. The Company accounts for stock-based payments to Scientific Advisory Committee members and consultants by determining the value of the stock compensation based upon the measurement date at either (a) the date at which a performance commitment is reached or (b) at the date at which the necessary performance to earn the equity instruments is complete.   Stock grants, which are generally time vested, are measured at the grant date fair value and charged to operations ratably over the vesting period.    Stock options granted to members of the Company’s Scientific Advisory Committee and to outside consultants are revalued each reporting period to determine the amount to be recorded as an expense in the respective period. As the stock options vest, they are valued on each vesting date and an adjustment is recorded for the difference between the value already recorded and the value on the date of vesting.   The fair value of common stock issued as stock-based compensation is determined by reference to the closing price of the Company’s common stock on the date of issuance. The fair value of stock options granted as stock-based compensation is determined utilizing the Black-Scholes option-pricing model, and is affected by several variables, the most significant of which are the life of the equity award, the exercise price of the stock option as compared to the fair market value of the common stock on the grant date, and the estimated volatility of the common stock over the term of the equity award. Estimated volatility is based on the historical volatility of the Company’s common stock. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant. The fair market value of common stock is determined by reference to the quoted market price of the Company’s common stock.   The Company recognizes the fair value of stock-based compensation awards in general and administrative costs and in research and development costs, as appropriate, in the Company’s consolidated statements of operations. The Company issues new shares of common stock to satisfy stock option exercises.

Earnings (Loss) Per Share   The Company’s computation of earnings (loss) per share (“EPS”) includes basic and diluted EPS. Basic EPS is measured as the income (loss) attributable to common stockholders divided by the weighted average common shares outstanding for the period. Diluted EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares (e.g., preferred shares, warrants and stock options) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS.   Loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the respective periods. Basic and diluted loss per common share is the same for all periods presented because all preferred shares, warrants and stock options outstanding are anti-dilutive.   At March 31, 2019 and 2018, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive.   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">March 31,</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2019</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2018</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 63%; line-height: 107%">Series A Convertible Preferred Stock</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 15%; text-align: right; line-height: 107%">4,375,000</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 15%; text-align: right; line-height: 107%">4,375,000</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Common stock warrants</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">9,000,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">—</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Common stock options, including options issued in the form of warrants</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">7,750,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">7,470,000</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Total</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">21,125,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">11,845,000</td> <td style="line-height: 107%"> </td></tr> </table>

Fair Value of Financial Instruments   The authoritative guidance with respect to fair value established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels and requires that assets and liabilities carried at fair value be classified and disclosed in one of three categories, as presented below. Disclosure as to transfers in and out of Levels 1 and 2, and activity in Level 3 fair value measurements, is also required.   Level 1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities and exchange-based derivatives.   Level 2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities, non-exchange-based derivatives, mutual funds, and fair-value hedges.   Level 3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently-traded non-exchange-based derivatives and commingled investment funds and are measured using present value pricing models.   The Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company performs an analysis of the assets and liabilities at each reporting period end.   The carrying value of financial instruments (consisting of cash and cash equivalents, and accounts payable and accrued expenses) is considered to be representative of their respective fair values due to the short-term nature of those instruments.

Recent Accounting Pronouncements   In June 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update 2018-07, Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting (“ASU 2018-07”). ASU 2018-07 expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. ASU 2018-07 also clarifies that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Revenue from Contracts with Customers (Topic 606). ASU 2018-07 was effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company adopted the provisions of ASU 2018-07 in the quarter beginning January 1, 2019. The adoption of ASU 2018-07 did not have any impact on the Company’s financial statement presentation or disclosures.   Management does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the Company’s financial statement presentation or disclosures.

At March 31, 2019 and 2018, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive.   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">March 31,</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2019</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2018</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 63%; line-height: 107%">Series A Convertible Preferred Stock</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 15%; text-align: right; line-height: 107%">4,375,000</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 15%; text-align: right; line-height: 107%">4,375,000</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Common stock warrants</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">9,000,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">—</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Common stock options, including options issued in the form of warrants</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">7,750,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">7,470,000</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Total</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">21,125,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">11,845,000</td> <td style="line-height: 107%"> </td></tr> </table>

350000

10.00 10.00

17500000

4375000

67045814 true false false

200000

1750000 6500000 P1Y P2Y 0.025 2294

9174

11468

9175

1897000 0.40

50000

100000

32964

954000 44870 44870

3283000

4000 10000 4000 4000 15000 18348 25000 25000 25000

8. Subsequent Events   Effective March 8, 2019, the Company entered into a Master Services Agreement with Triligent International (“Triligent”) for services associated with certain of the Company’s projected, current and/or future pre-clinical and/or clinical studies, for a period of three years and renewable for an additional three-year term, and terminable by either party. Triligent will invoice the Company for time and expenses on a monthly basis.   Effective April 5, 2019, pursuant to the terms of the Master Services Agreement, the Company finalized a work order agreement with Triligent to assist the Company in pre-study commencement medical writing projects, including the development of study protocols and model informed consent forms in connection with a clinical research proposal. The total cost of this work order is not expected to exceed $10,500.   Effective April 9, 2019, the Company entered into a consulting agreement with Theradex for consulting services associated with the Company’s worldwide development of LB-100, which is expected to be completed by July 1, 2020. Pursuant to the terms of the consulting agreement, Theradex will invoice the Company for time and expenses on a monthly basis.   The Company performed an evaluation of subsequent events through the date of filing of these consolidated financial statements with the SEC. There were no material subsequent events which affected, or could affect, the amounts or disclosures in the consolidated financial statements.

A summary of common stock warrant activity, including warrants to purchase common stock that were issued in conjunction with the Company’s private placements, during the three months ended March 31, 2019 is presented below.   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Number of Shares</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Weighted Average Exercise Price</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Weighted Average Remaining Contractual Life (in Years)</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 46%; line-height: 107%">Warrants outstanding at December 31, 2018</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 12%; text-align: right; line-height: 107%">9,000,000</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 12%; text-align: right; line-height: 107%">1.000</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 21%; text-align: right; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Issued</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">—</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">—</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Exercised</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">—</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">—</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Expired</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">—</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">—</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Warrants outstanding at March 31, 2019</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">9,000,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">1.000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">3.67</td> <td style="line-height: 107%"> </td></tr> </table>

100000 50000 50000 50000 The Company will be obligated to pay Moffitt earned royalties of 4% on worldwide cumulative net sales of royalty-bearing products, subject to reduction to 2% under certain circumstances, on a quarterly basis, with a minimum royalty payment of $50,000 in the first four years after sales commence, and $100,000 in year five and each year thereafter, subject to reduction by 40% under certain circumstances relating to the status of Valid Claims, as such term is defined in the License Agreement.

57070

61433

3954835

4334445

2293

3954835

4336738

210673

195211

34139 15704

244812

210915

3500000

6704

25280598

25267662

-25077279

-24648543

3954835

4336738

4161

390428

354070

438742

379759

-438742

-379759

10006

599

-0.01

67045814

58025814

12936

-6656

-15796

15462

-123546

18435 -10800

-379408

-497710

-379408

-497710

2. Business   The Company is a drug discovery company that uses biomarker technology to identify enzyme targets associated with serious common diseases and then designs novel compounds to attack those targets. The Company’s product pipeline encompasses two major categories of compounds at various stages of pre-clinical and clinical development that the Company believes have broad therapeutic potential not only for cancer but also for other debilitating and life-threatening diseases.   The Company’s activities are subject to significant risks and uncertainties, including the need for additional capital, as described below. The Company has not yet commenced any revenue-generating operations, does not have positive cash flows from operations, and is dependent on periodic infusions of equity capital to fund its operating requirements.   The Company’s common stock is traded on the OTCQB operated by the OTC Markets under the symbol “LIXT”.   Going Concern   The Company’s consolidated financial statements have been presented on the basis that it is a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has not generated any revenues from operations to date and does not expect to do so in the foreseeable future. Furthermore, the Company has experienced recurring operating losses and negative operating cash flows since inception and has financed its working capital requirements during this period primarily through the recurring sale of its equity securities and the exercise of outstanding common stock options and purchase warrants.   As a result, management has concluded that there is substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the consolidated financial statements are being issued. In addition, the Company’s independent registered public accounting firm, in their report on the Company’s consolidated financial statements for the year ended December 31, 2018, has also expressed substantial doubt about the Company’s ability to continue as a going concern.   The Company’s ability to continue as a going concern is dependent upon its ability to raise additional equity capital to fund its research and development activities and to ultimately achieve sustainable operating revenues and profits. The Company’s consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.   Because the Company is currently engaged in clinical research at a relatively early stage, it will likely take a significant amount of time to develop any product or intellectual property capable of generating sustainable revenues. Accordingly, the Company’s business is unlikely to generate any sustainable operating revenues in the next several years and may never do so. In addition, to the extent that the Company is able to generate revenues through licensing its technologies or through product sales, there can be no assurance that the Company will be able to achieve positive earnings and operating cash flows.   Effective November 30, 2018, the Company raised $4,500,000 through the sale to sixteen accredited investors of 9,000,000 units at a purchase price of $0.50 per unit. Each unit consisted of one share of common stock and one four-year warrant to purchase one share of common stock at an exercise price of $1.00 per share. Accordingly, a total of 9,000,000 shares of common stock and warrants to purchase 9,000,000 shares of common stock were issued by the Company. The warrants do not have any reset provisions.   At March 31, 2019, the Company had cash and cash equivalents of $3,893,604 available to fund its operations. The next step in the development of the Company’s lead anti-cancer clinical compound LB-100 is to evaluate its therapeutic benefit in Phase 1b/2 clinical trials. The initial clinical trial evaluating LB-100 in myelodysplastic syndrome (MDS) began during April 2019 and is expected to complete patient accrual over a period of two years, with final analysis and reporting expected within three years. The Company’s longer-term objective is to secure one or more strategic partnerships with pharmaceutical companies with major programs in cancer.   The amount and timing of future cash requirements will depend on the pace and design of the Company’s clinical trial program. As market conditions present uncertainty as to the Company’s ability to secure additional funds, there can be no assurances that the Company will be able to secure additional financing on acceptable terms, or at all, as and when necessary to continue to conduct operations. If cash resources are insufficient to satisfy the Company’s ongoing cash requirements, the Company would be required to scale back or discontinue its technology and product development programs and/or any clinical trials, or obtain funds, if available (although there can be no certainty), through strategic alliances that may require the Company to relinquish rights to certain of its compounds, or to discontinue its operations entirely.

10500

4161

4500000

9000000

0.50

Each unit consisted of one share of common stock and one four-year warrant to purchase one share of common stock at an exercise price of $1.00 per share.

1.00

9000000

Costs under this work order agreement are estimated to be approximately $954,000, with such payments expected to be divided approximately 94% to Theradex for services and approximately 6% for payments for pass-through costs. 32964 190773 217659

0.10

P180M

21125000

11845000

4375000

9000000

7750000

4375000

7470000

175000 0.01 175000 9650000 12.5 21875000

4375000

1.000

0.90

9000000

1.000 1.000 P3Y8M2D

15000

1.00

0.50

0.545

P5Y

P3Y4M28D

2000000

2024-01-28

12000

12936

7550000

0.583

0.538

P3Y5M5D

0.120

0.150

0.160

0.200

0.250

0.280

0.500

1.000

2.000

7750000

450000

300000

200000

500000

400000

4400000

500000

7550000

450000

300000

200000

500000

200000

4400000

500000

12936

0.90

15274

EX-101.SCH 5 lixt-20190331.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Organization and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Business link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Business (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Summary of Significant Accounting Policies - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Stockholders' Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Stockholders' Equity - Schedule of Warrants Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Stock-Based Compensation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity Including Options Form of Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Stock-Based Compensation - Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 lixt-20190331_cal.xml XBRL CALCULATION FILE EX-101.DEF 7 lixt-20190331_def.xml XBRL DEFINITION FILE EX-101.LAB 8 lixt-20190331_lab.xml XBRL LABEL FILE Award Type [Axis] 2007 Stock Compensation Plan [Member] Related Party [Axis] NDA Consulting Corp [Member] Related Party Transaction [Axis] Collaboration Agreement BioPharmaWorks LLC [Member] Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Accumulated Deficit [Member] Type of Arrangement and Non-arrangement Transactions [Axis] Materials Cooperative Research and Development Agreement [Member] Consulting Agreement [Member] Title of Individual [Axis] Mr. Schwartzberg [Member] Option Indexed to Issuer's Equity, Type [Axis] Employee Stock Option [Member] Material Transfer Agreement [Member] Legal Entity [Axis] INSERM [Member] Plan Name [Axis] Development Milestones [Member] Range [Axis] Maximum [Member] Commercial Milestones [Member] First Installment [Member] Second Installment [Member] Class of Stock [Axis] Series A Convertible Preferred Stock [Member] Consulting Agreement with Liberi Life Consultancy BV [Member] EURO [Member] Winson Sze Chun Ho [Member] Dr. Yun Yen [Member] Award Date [Axis] August 4, 2019 [Member] Vesting [Axis] First Four Years [Member] Five Years and Thereafter [Member] Work Order Agreement [Member] Theradex Systems, Inc [Member] Sixteen Accredited Investors [Member] Common Stock Warrants [Member] Subsequent Event Type [Axis] Subsequent Event [Member] License Agreement [Member] Moffitt Cancer Center and Research Institute Hospital Inc [Member] Antidilutive Securities [Axis] Common Stock Options, Including Options Issued in the Form of Warrants [Member] Preferred Stock [Member] Common Stock Warrant [Member] Dr. John Kovach [Member] Eric Forman [Member] Directors, Officers, Affiliates and Related Parties [Member] Exercise Price Range [Axis] Exercise Price One [Member] Exercise Price Two [Member] Exercise Price Three [Member] Exercise Price Four [Member] Exercise Price Five [Member] Exercise Price Six [Member] Exercise Price Seven [Member] Exercise Price Eight [Member] Exercise Price Nine [Member] Minimum [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Filer Category Entity Small Business Flag Entity Emerging Growth Company Entity Ex Transition Period Entity Common Stock, Shares Outstanding Trading Symbol Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS Current assets: Cash and cash equivalents Accrued interest receivable Prepaid expenses and other current assets Total current assets Prepaid expense, less current portion Total assets LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable and accrued expenses Research and development contract liabilities Total current liabilities Commitments and contingencies Stockholders' equity: Preferred Stock, $0.0001 par value; authorized - 10,000,000 shares; issued and outstanding - 350,000 shares of Series A Convertible Preferred Stock, $10.00 per share stated value, $50.00 per share cash redemption value; aggregate cash redemption value - $17,500,000; liquidation preference based on assumed conversion into common shares - 4,375,000 shares Common stock, $0.0001 par value; authorized - 100,000,000 shares; issued and outstanding - 67,045,814 shares Additional paid-in capital Accumulated deficit Total stockholders' equity Total liabilities and stockholders' equity Statement [Table] Statement [Line Items] Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Preferred stock, stated value Preferred stock, per share redemption price Preferred stock, aggregate cash redemption value Preferred stock, issuable upon conversion Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Revenues Costs and expenses: General and administrative costs, including $12,000 and $12,000 to related parties for the three months ended March 31, 2019 and 2018, respectively Research and development costs, including $33,897 and $0 to Theradex for the three months ended March 31, 2019 and 2018, respectively Total costs and expenses Loss from operations Interest income Net loss Net loss per common share - basic and diluted Weighted average common shares outstanding - basic and diluted General and administrative costs, to related parties Research and development costs, to Theradex Balance Balance, shares Stock-based compensation expense Net loss Balance Balance, shares Statement of Cash Flows [Abstract] Cash flows from operating activities: Adjustments to reconcile net loss to net cash used in operating activities: Stock-based compensation expense included in - General and administrative costs Stock-based compensation expense included in - Research and development costs Changes in operating assets and liabilities: (Increase) decrease in - Accrued interest receivable Prepaid expenses and other current assets Increase (decrease) in - Accounts payable and accrued expenses Research and development contract liabilities Net cash used in operating activities Cash and cash equivalents: Net decrease Balance at beginning of period Balance at end of period Supplemental disclosures of cash flow information: Cash paid for - Interest Income taxes Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization and Basis of Presentation Business Accounting Policies [Abstract] Summary of Significant Accounting Policies Equity [Abstract] Stockholders' Equity Related Party Transactions [Abstract] Related Party Transactions Share-based Payment Arrangement [Abstract] Stock-Based Compensation Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Subsequent Events [Abstract] Subsequent Events Principles of Consolidation Use of Estimates Cash and Cash Equivalents Research and Development Patent and Licensing Costs Concentration of Risk Income Taxes Stock-Based Compensation Earnings (Loss) Per Share Fair Value of Financial Instruments Recent Accounting Pronouncements Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share Schedule of Warrants Outstanding Summary of Stock Option Activity Including Options Form of Warrants Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants Sale of stock during period, amount Sale of stock during period, shares Equity issuance price per share Common stock units, description Warrants exercise price Number of common stock issued Warrants to purchase common stock Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Costs under work EX-101.PRE 9 lixt-20190331_pre.xml XBRL PRESENTATION FILE XML 10 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2019	May 01, 2019
Document And Entity Information
Entity Registrant Name	LIXTE BIOTECHNOLOGY HOLDINGS, INC.
Entity Central Index Key	0001335105
Document Type	10-Q
Document Period End Date	Mar. 31, 2019
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		67,045,814
Trading Symbol	LIXT
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2019

XML 11 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 3,893,604	$ 4,273,012
Accrued interest receivable	4,161
Prepaid expenses and other current assets	57,070	61,433
Total current assets	3,954,835	4,334,445
Prepaid expense, less current portion		2,293
Total assets	3,954,835	4,336,738
Current liabilities:
Accounts payable and accrued expenses	210,673	195,211
Research and development contract liabilities	34,139	15,704
Total current liabilities	244,812	210,915
Commitments and contingencies
Stockholders' equity:
Preferred Stock, $0.0001 par value; authorized - 10,000,000 shares; issued and outstanding - 350,000 shares of Series A Convertible Preferred Stock, $10.00 per share stated value, $50.00 per share cash redemption value; aggregate cash redemption value - $17,500,000; liquidation preference based on assumed conversion into common shares - 4,375,000 shares	3,500,000	3,500,000
Common stock, $0.0001 par value; authorized - 100,000,000 shares; issued and outstanding - 67,045,814 shares	6,704	6,704
Additional paid-in capital	25,280,598	25,267,662
Accumulated deficit	(25,077,279)	(24,648,543)
Total stockholders' equity	3,710,023	4,125,823
Total liabilities and stockholders' equity	$ 3,954,835	$ 4,336,738

XML 12 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	67,045,814	67,045,814
Common stock, shares outstanding	67,045,814	67,045,814
Series A Convertible Preferred Stock [Member]
Preferred stock, shares issued	350,000	350,000
Preferred stock, shares outstanding	350,000	350,000
Preferred stock, stated value	$ 10.00	$ 10.00
Preferred stock, per share redemption price	$ 50.00	$ 50.00
Preferred stock, aggregate cash redemption value	$ 17,500,000	$ 17,500,000
Preferred stock, issuable upon conversion	4,375,000	4,375,000

XML 13 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Income Statement [Abstract]
Revenues
Costs and expenses:
General and administrative costs, including $12,000 and $12,000 to related parties for the three months ended March 31, 2019 and 2018, respectively	390,428	354,070
Research and development costs, including $33,897 and $0 to Theradex for the three months ended March 31, 2019 and 2018, respectively	48,314	25,689
Total costs and expenses	438,742	379,759
Loss from operations	(438,742)	(379,759)
Interest income	10,006	599
Net loss	$ (428,736)	$ (379,160)
Net loss per common share - basic and diluted	$ (0.01)	$ (0.01)
Weighted average common shares outstanding - basic and diluted	67,045,814	58,025,814

XML 14 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Income Statement [Abstract]
General and administrative costs, to related parties	$ 12,000	$ 12,000
Research and development costs, to Theradex	$ 33,897	$ 0

XML 15 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)	Series A Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2017	$ 3,500,000	$ 5,802	$ 20,004,654	$ (22,515,415)	$ 995,041
Balance, shares at Dec. 31, 2017	350,000	58,025,814
Net loss				(379,160)	(379,160)
Balance at Mar. 31, 2018	$ 3,500,000	$ 5,802	20,004,654	(22,894,575)	615,881
Balance, shares at Mar. 31, 2018	350,000	58,025,814
Balance at Dec. 31, 2018	$ 3,500,000	$ 6,704	25,267,662	(24,648,543)	4,125,823
Balance, shares at Dec. 31, 2018	350,000	67,045,814
Stock-based compensation expense			12,936		12,936
Net loss				(428,736)	(428,736)
Balance at Mar. 31, 2019	$ 3,500,000	$ 6,704	$ 25,280,598	$ (25,077,279)	$ 3,710,023
Balance, shares at Mar. 31, 2019	350,000	67,045,814

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

XML 16 R7.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Cash flows from operating activities:
Net loss	$ (428,736)	$ (379,160)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense included in - General and administrative costs	12,936
Stock-based compensation expense included in - Research and development costs
(Increase) decrease in -
Accrued interest receivable	(4,161)
Prepaid expenses and other current assets	6,656	15,796
Increase (decrease) in -
Accounts payable and accrued expenses	15,462	(123,546)
Research and development contract liabilities	18,435	(10,800)
Net cash used in operating activities	(379,408)	(497,710)
Cash and cash equivalents:
Net decrease	(379,408)	(497,710)
Balance at beginning of period	4,273,012	1,305,748
Balance at end of period	3,893,604	808,038
Supplemental disclosures of cash flow information:
Interest
Income taxes

XML 17 R8.htm IDEA: XBRL DOCUMENT

Organization and Basis of Presentation

3 Months Ended

Mar. 31, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization and Basis of Presentation

1. Organization and Basis of Presentation

XML 18 R9.htm IDEA: XBRL DOCUMENT

Business

3 Months Ended

Mar. 31, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Business

2. Business

The Company’s common stock is traded on the OTCQB operated by the OTC Markets under the symbol “LIXT”.

Going Concern

XML 19 R10.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2019

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

3. Summary of Significant Accounting Policies

Principles of Consolidation

Use of Estimates

Cash and Cash Equivalents

Research and Development

Patent and Licensing Costs

Concentration of Risk

Costs incurred pursuant to the agreements with Theradex are included in research and development costs in the Company’s consolidated statements of operations.

Income Taxes

Stock-Based Compensation

Stock grants, which are generally time vested, are measured at the grant date fair value and charged to operations ratably over the vesting period.

Earnings (Loss) Per Share

	March 31,
	2019		2018

Series A Convertible Preferred Stock		4,375,000		4,375,000
Common stock warrants		9,000,000		—
Common stock options, including options issued in the form of warrants		7,750,000		7,470,000
Total		21,125,000		11,845,000

Fair Value of Financial Instruments

Recent Accounting Pronouncements

XML 20 R11.htm IDEA: XBRL DOCUMENT

Stockholders' Equity

3 Months Ended

Mar. 31, 2019

Equity [Abstract]

Stockholders' Equity

4. Stockholders’ Equity

Preferred Stock

Common Stock

Common Stock Warrants

	Number of Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (in Years)

Warrants outstanding at December 31, 2018		9,000,000	$	1.000
Issued		—		—
Exercised		—		—
Expired		—		—
Warrants outstanding at March 31, 2019		9,000,000	$	1.000		3.67

At March 31, 2019, all outstanding warrants are exercisable at $1.000 per common share.

Information with respect to the issuance of common stock in connection with various stock-based compensation arrangements is provided at Note 6.

XML 21 R12.htm IDEA: XBRL DOCUMENT

Related Party Transactions

3 Months Ended

Mar. 31, 2019

Related Party Transactions

5. Related Party Transactions

XML 22 R13.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation

3 Months Ended

Mar. 31, 2019

Share-based Payment Arrangement [Abstract]

Stock-Based Compensation

6. Stock-Based Compensation

The Company issues common stock and stock options as incentive compensation to directors and as compensation for the services of independent contractors and consultants of the Company.

There were no stock options requiring an assessment of value during the three months ended March 31, 2019 and 2018.

Total stock-based compensation expense was $12,936 and $0 for the three months ended March 31, 2019 and 2018, respectively.

A summary of stock option activity, including options issued in the form of warrants, during the three months ended March 31, 2019 is presented below.

	Number of Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (in Years)

Stock options outstanding at December 31, 2018		7,750,000	$	0.583
Granted		—		—
Exercised		—		—
Expired		—		—
Stock options outstanding at March 31, 2019		7,750,000	$	0.538		3.43

Stock options exercisable at March 31, 2019		7,550,000	$	0.545		3.41

The exercise prices of common stock options outstanding and exercisable, including options issued in the form of warrants, are as follows at March 31, 2019:

Exercise Prices		Options Outstanding (Shares)		Options Exercisable (Shares)

$	0.120		450,000		450,000
$	0.150		300,000		300,000
$	0.160		200,000		200,000
$	0.200		500,000		500,000
$	0.250		500,000		500,000
$	0.280		400,000		200,000
$	0.500		4,400,000		4,400,000
$	1.000		500,000		500,000
$	2.000		500,000		500,000
			7,750,000		7,550,000

The intrinsic value of exercisable but unexercised in-the-money stock options at March 31, 2019 was approximately $3,283,000, based on a fair market value of $0.90 per share on March 31, 2019.

Outstanding options to acquire 200,000 shares of the Company’s common stock had not vested at March 31, 2019.

The Company expects to satisfy such stock obligations through the issuance of authorized but unissued shares of common stock.

XML 23 R14.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

3 Months Ended

Mar. 31, 2019

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

7. Commitments and Contingencies

Legal claims

Significant agreements and contracts

XML 24 R15.htm IDEA: XBRL DOCUMENT

Subsequent Events

3 Months Ended

Mar. 31, 2019

Subsequent Events [Abstract]

Subsequent Events

8. Subsequent Events

XML 25 R16.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2019

Accounting Policies [Abstract]

Principles of Consolidation

Principles of Consolidation

Use of Estimates

Use of Estimates

Cash and Cash Equivalents

Cash and Cash Equivalents

Research and Development

Research and Development

Patent and Licensing Costs

Patent and Licensing Costs

Concentration of Risk

Concentration of Risk

Costs incurred pursuant to the agreements with Theradex are included in research and development costs in the Company’s consolidated statements of operations.

Income Taxes

Income Taxes

Stock-Based Compensation

Stock-Based Compensation

Stock grants, which are generally time vested, are measured at the grant date fair value and charged to operations ratably over the vesting period.

Earnings (Loss) Per Share

Earnings (Loss) Per Share

	March 31,
	2019		2018

Series A Convertible Preferred Stock		4,375,000		4,375,000
Common stock warrants		9,000,000		—
Common stock options, including options issued in the form of warrants		7,750,000		7,470,000
Total		21,125,000		11,845,000

Fair Value of Financial Instruments

Fair Value of Financial Instruments

Recent Accounting Pronouncements

Recent Accounting Pronouncements

XML 26 R17.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2019

Accounting Policies [Abstract]

Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share

	March 31,
	2019		2018

Series A Convertible Preferred Stock		4,375,000		4,375,000
Common stock warrants		9,000,000		—
Common stock options, including options issued in the form of warrants		7,750,000		7,470,000
Total		21,125,000		11,845,000

XML 27 R18.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Tables)

3 Months Ended

Mar. 31, 2019

Equity [Abstract]

Schedule of Warrants Outstanding

	Number of Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (in Years)

Warrants outstanding at December 31, 2018		9,000,000	$	1.000
Issued		—		—
Exercised		—		—
Expired		—		—
Warrants outstanding at March 31, 2019		9,000,000	$	1.000		3.67

XML 28 R19.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Tables)

3 Months Ended

Mar. 31, 2019

Share-based Payment Arrangement [Abstract]

Summary of Stock Option Activity Including Options Form of Warrants

A summary of stock option activity, including options issued in the form of warrants, during the three months ended March 31, 2019 is presented below.

	Number of Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (in Years)

Stock options outstanding at December 31, 2018		7,750,000	$	0.583
Granted		—		—
Exercised		—		—
Expired		—		—
Stock options outstanding at March 31, 2019		7,750,000	$	0.538		3.43

Stock options exercisable at March 31, 2019		7,550,000	$	0.545		3.41

Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants

The exercise prices of common stock options outstanding and exercisable, including options issued in the form of warrants, are as follows at March 31, 2019:

Exercise Prices		Options Outstanding (Shares)		Options Exercisable (Shares)

$	0.120		450,000		450,000
$	0.150		300,000		300,000
$	0.160		200,000		200,000
$	0.200		500,000		500,000
$	0.250		500,000		500,000
$	0.280		400,000		200,000
$	0.500		4,400,000		4,400,000
$	1.000		500,000		500,000
$	2.000		500,000		500,000
			7,750,000		7,550,000

XML 29 R20.htm IDEA: XBRL DOCUMENT

Business (Details Narrative) - USD ($)	Nov. 30, 2018	Mar. 31, 2019	Dec. 31, 2018	Mar. 31, 2018	Dec. 31, 2017
Cash and cash equivalents		$ 3,893,604	$ 4,273,012	$ 808,038	$ 1,305,748
Sixteen Accredited Investors [Member]
Sale of stock during period, amount	$ 4,500,000
Sale of stock during period, shares	9,000,000
Equity issuance price per share	$ 0.50
Common stock units, description	Each unit consisted of one share of common stock and one four-year warrant to purchase one share of common stock at an exercise price of $1.00 per share.
Warrants exercise price	$ 1.00
Number of common stock issued	9,000,000
Warrants to purchase common stock	9,000,000

XML 30 R21.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details Narrative) - USD ($)		3 Months Ended
	Sep. 12, 2018	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Patent and licensing costs		$ 190,773	$ 217,659
Minimum concentration of risk percent		10.00%
Deferred setup and organization costs, amortization period		180 months
Unrecognized tax benefits
Theradex Systems, Inc [Member]
Costs under work		$ 44,870
Research and development, description		Costs under this work order agreement are estimated to be approximately $954,000, with such payments expected to be divided approximately 94% to Theradex for services and approximately 6% for payments for pass-through costs.
Payment for work order costs		$ 32,964
Work Order Agreement [Member] \| Theradex Systems, Inc [Member]
Costs under work	$ 954,000	$ 44,870

XML 31 R22.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Anti-dilutive securities excluded from computation of earnings per share	21,125,000	11,845,000
Series A Convertible Preferred Stock [Member]
Anti-dilutive securities excluded from computation of earnings per share	4,375,000	4,375,000
Common Stock Warrants [Member]
Anti-dilutive securities excluded from computation of earnings per share	9,000,000
Common Stock Options, Including Options Issued in the Form of Warrants [Member]
Anti-dilutive securities excluded from computation of earnings per share	7,750,000	7,470,000

XML 32 R23.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Details Narrative) - USD ($)		3 Months Ended
Stockholders' Equity (Details Narrative) - USD ($)	Mar. 17, 2015	Mar. 31, 2019	Dec. 31, 2018	Jan. 28, 2016
Preferred stock, shares authorized		10,000,000	10,000,000
Preferred stock, par value		$ 0.0001	$ 0.0001
Common stock, shares authorized		100,000,000	100,000,000
Common stock, par value		$ 0.0001	$ 0.0001
Common stock, shares issued		67,045,814	67,045,814
Common stock, shares outstanding		67,045,814	67,045,814
Common Stock Warrant [Member]
Outstanding warrants exercisable price per share		$ 1.000
Common stock price per share		$ 0.90
Series A Convertible Preferred Stock [Member]
Preferred stock, shares authorized	175,000
Number of share tranche of the series a convertible preferred stock receive a per share dividend	175,000
Percentage of dividend from annual revenue	1.00%
Annual net revenue divided by converted or redeemed shares	175,000
Preferred shares converted to common stock conversion rate		12.5
Gross proceeds need to trigger mandatory conversion of series a preferred		$ 21,875,000
Preferred stock, shares outstanding		350,000	350,000
Preferred stock convertible into common stock		4,375,000
Preferred stock, per share redemption price		$ 50.00	$ 50.00
Series A Convertible Preferred Stock [Member] \| Minimum [Member]
Preferred stock, shares authorized				175,000
Series A Convertible Preferred Stock [Member] \| Maximum [Member]
Preferred stock, shares authorized				350,000
Preferred Stock [Member]
Undesignated preferred stock, shares		9,650,000

XML 33 R24.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Schedule of Warrants Outstanding (Details) - Common Stock Warrants [Member]	3 Months Ended
	Mar. 31, 2019 $ / shares shares
Number of Shares, Warrants Outstanding, Beginning Balance \| shares	9,000,000
Number of Shares, Issued \| shares
Number of Shares, Exercised \| shares
Number of Shares, Expired \| shares
Number of Shares, Warrants Outstanding, Ending Balance \| shares	9,000,000
Weighted Average Exercise Price, Outstanding, Beginning \| $ / shares	$ 1.000
Weighted Average Exercise Price, Issued \| $ / shares
Weighted Average Exercise Price, Exercised \| $ / shares
Weighted Average Exercise Price, Expired \| $ / shares
Weighted Average Exercise Price, Outstanding, Ending \| $ / shares	$ 1.000
Weighted Average Remaining Contractual Life (in Years), Outstanding	3 years 8 months 2 days

XML 34 R25.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details Narrative) - USD ($)			3 Months Ended
	Aug. 02, 2018	Jan. 28, 2014	Mar. 31, 2019	Mar. 31, 2018	Jan. 28, 2015
Eric Forman [Member]
Legal and consulting fees charged to operations for services rendered			$ 12,000	$ 12,000
Dr. John Kovach [Member]
Salaries paid			$ 15,000	15,000
Percentage of devoting business activities			100.00%
Mr. Schwartzberg [Member] \| Consulting Agreement [Member]
Stock options granted to purchase common stock		4,000,000
Options, exercisable price per share		$ 0.50
Options exercisable period		5 years
Number of stock options vested		2,000,000			2,000,000
Option extended period	Jan. 28, 2024
Directors, Officers, Affiliates and Related Parties [Member]
Stock-based compensation expense			$ 12,936	$ 0

XML 35 R26.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Details Narrative) - USD ($)			3 Months Ended
Stock-Based Compensation (Details Narrative) - USD ($)	Aug. 04, 2018	Jun. 20, 2007	Mar. 31, 2019	Mar. 31, 2018
Stock based compensation			$ 12,936	$ 0
Total deferred compensation expense for outstanding value of unvested stock options			18,000
Intrinsic value of exercisable but unexercised in-the-money stock options			$ 3,283,000
Fair market value, per share			$ 0.90
Stock option outstanding acquired common stock			200,000
Winson Sze Chun Ho [Member]
Stock options granted to purchase common stock, issued	200,000
Stock options are exercisable price per share	$ 0.28
Stock option vested exercisable term	5 years
Number of fully vested option issued	100,000
Fair value of stock options	$ 104,920
Stock price per share	$ 0.2623
Stock options fully vested amount, fair value	$ 52,460
Charges to operations			$ 12,936
Winson Sze Chun Ho [Member] \| August 4, 2019 [Member]
Number of fully vested option issued	100,000
Dr. Yun Yen [Member]
Stock options granted to purchase common stock, issued	200,000
Stock options are exercisable price per share	$ 0.28
Stock option vested exercisable term	5 years
Number of fully vested option issued	100,000
Fair value of stock options	$ 104,920
Stock price per share	$ 0.2623
Stock options fully vested amount, fair value	$ 52,460
Charges to operations			$ 12,936
Dr. Yun Yen [Member] \| August 4, 2019 [Member]
Number of fully vested option issued			100,000
2007 Stock Compensation Plan [Member]
Number of restricted stock issued		2,500,000
Stock options granted to purchase common stock, issued			1,250,000
Stock options granted to purchase common stock, outstanding			1,250,000

XML 36 R27.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Summary of Stock Option Activity Including Options Form of Warrants (Details) - Employee Stock Option [Member]	3 Months Ended
	Mar. 31, 2019 $ / shares shares
Number of Shares, Stock options outstanding, at the Beginning \| shares	7,750,000
Number of Shares, Granted \| shares
Number of Shares, Exercised \| shares
Number of Shares, Expired \| shares
Number of Shares, Stock options outstanding, at the End \| shares	7,750,000
Number of Shares, Stock options exercisable, at the End \| shares	7,550,000
Weighted Average Exercise Price, Stock options outstanding, at the Beginning \| $ / shares	$ 0.583
Weighted Average Exercise Price, Granted \| $ / shares
Weighted Average Exercise Price, Exercised \| $ / shares
Weighted Average Exercise Price, Expired \| $ / shares
Weighted Average Exercise Price, Stock options outstanding, at the End \| $ / shares	0.538
Weighted Average Exercise Price, Stock options exercisable, at the End \| $ / shares	$ 0.545
Weighted Average Remaining Contractual Life (in Years), Stock options outstanding	3 years 5 months 5 days
Weighted Average Remaining Contractual Life (in Years), Stock options exercisable	3 years 4 months 28 days

XML 37 R28.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants (Details)	3 Months Ended
	Mar. 31, 2019 $ / shares shares
Options Outstanding (Shares)	7,750,000
Options Exercisable (Shares)	7,550,000
Exercise Price One [Member]
Exercise Prices \| $ / shares	$ 0.120
Options Outstanding (Shares)	450,000
Options Exercisable (Shares)	450,000
Exercise Price Two [Member]
Exercise Prices \| $ / shares	$ 0.150
Options Outstanding (Shares)	300,000
Options Exercisable (Shares)	300,000
Exercise Price Three [Member]
Exercise Prices \| $ / shares	$ 0.160
Options Outstanding (Shares)	200,000
Options Exercisable (Shares)	200,000
Exercise Price Four [Member]
Exercise Prices \| $ / shares	$ 0.200
Options Outstanding (Shares)	500,000
Options Exercisable (Shares)	500,000
Exercise Price Five [Member]
Exercise Prices \| $ / shares	$ 0.250
Options Outstanding (Shares)	500,000
Options Exercisable (Shares)	500,000
Exercise Price Six [Member]
Exercise Prices \| $ / shares	$ 0.280
Options Outstanding (Shares)	400,000
Options Exercisable (Shares)	200,000
Exercise Price Seven [Member]
Exercise Prices \| $ / shares	$ 0.500
Options Outstanding (Shares)	4,400,000
Options Exercisable (Shares)	4,400,000
Exercise Price Eight [Member]
Exercise Prices \| $ / shares	$ 1.000
Options Outstanding (Shares)	500,000
Options Exercisable (Shares)	500,000
Exercise Price Nine [Member]
Exercise Prices \| $ / shares	$ 2.000
Options Outstanding (Shares)	500,000
Options Exercisable (Shares)	500,000

XML 38 R29.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details Narrative)													3 Months Ended		6 Months Ended	12 Months Ended
Commitments and Contingencies (Details Narrative)	Nov. 03, 2018 USD ($)	Sep. 12, 2018 USD ($)	Aug. 20, 2018 USD ($)	Jun. 14, 2018 USD ($)	Apr. 05, 2018 USD ($)	Apr. 05, 2018 EUR (€)	Apr. 02, 2018	Mar. 22, 2018 USD ($)	Jul. 09, 2017 USD ($)	Jun. 14, 2017 USD ($)	Sep. 14, 2015 USD ($)	Dec. 24, 2013 USD ($)	Mar. 31, 2019 USD ($)	Mar. 31, 2018 USD ($)	Jun. 30, 2018 USD ($)	Dec. 31, 2018 USD ($)
Accreted charges															$ 25,000
Research and development costs													$ 48,314	$ 25,689
Amortizing the retainer payment													2,294
Unamortized balance of the retainer payment													9,174			$ 11,468
Unamortized balance of the retainer payment classified as a current asset																9,175
Unamortized balance of the retainer payment classified as a non-current asset																2,293
Royalties description													The Company will be obligated to pay Moffitt earned royalties of 4% on worldwide cumulative net sales of royalty-bearing products, subject to reduction to 2% under certain circumstances, on a quarterly basis, with a minimum royalty payment of $50,000 in the first four years after sales commence, and $100,000 in year five and each year thereafter, subject to reduction by 40% under certain circumstances relating to the status of Valid Claims, as such term is defined in the License Agreement.
First Four Years [Member]
Minimum payments for royalties																50,000
Five Years and Thereafter [Member]
Minimum payments for royalties																$ 100,000
Collaboration Agreement BioPharmaWorks LLC [Member]
Research and development costs													$ 10,000	10,000
Consulting and advisory fee											$ 10,000
NDA Consulting Corp [Member]
Consulting and advisory fee												$ 4,000	4,000	4,000
Agreement term												1 year
Theradex Systems, Inc [Member]
Costs under work													44,870
Materials Cooperative Research and Development Agreement [Member]
Funds provide for use in acquiring technical, statistical and administrative support for research activities										$ 100,000
Research and development costs														$ 12,500
Materials Cooperative Research and Development Agreement [Member] \| First Installment [Member]
Paid two equal installments									$ 50,000
Materials Cooperative Research and Development Agreement [Member] \| Second Installment [Member]
Paid two equal installments				$ 50,000
Cancellation of installment, amount	$ 50,000
Material Transfer Agreement [Member] \| Development Milestones [Member] \| INSERM [Member] \| Maximum [Member]
Milestone payments								$ 1,750,000
Material Transfer Agreement [Member] \| Commercial Milestones [Member] \| INSERM [Member] \| Maximum [Member]
Milestone payments								$ 6,500,000
Consulting Agreement with Liberi Life Consultancy BV [Member]
Agreement term							2 years
Payment of a fixed, one-time retainer one time retainer					$ 18,348
Net payments of sales of products or licensing activities, percentage					2.50%	2.50%
Consulting Agreement with Liberi Life Consultancy BV [Member] \| EURO [Member]
Payment of a fixed, one-time retainer one time retainer \| €						€ 15,000
License Agreement [Member]
Amount charge to operations													15,274
License Agreement [Member] \| Moffitt Cancer Center and Research Institute Hospital Inc [Member]
Non-refundable license issue fee			$ 25,000
Annual license maintenance fee			25,000
Payments on non-refundable milestone			$ 1,897,000
Percentage of milestone			40.00%
Work Order Agreement [Member] \| Theradex Systems, Inc [Member]
Minimum payments for royalties													32,964
Costs under work		$ 954,000											$ 44,870

XML 39 R30.htm IDEA: XBRL DOCUMENT

Subsequent Events (Details Narrative)	Apr. 05, 2019 USD ($)
Subsequent Event [Member] \| Maximum [Member]
Total cost of work order	$ 10,500

EXCEL 40 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 41 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 42 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 43 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.1 html 117 176 1 false 50 0 false 5 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://lixte.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://lixte.com/role/BalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://lixte.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://lixte.com/role/StatementsOfOperations Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical) Sheet http://lixte.com/role/StatementsOfOperationsParenthetical Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical) Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) Sheet http://lixte.com/role/StatementsOfStockholdersEquity Condensed Consolidated Statements of Stockholders' Equity (Unaudited) Statements 6 false false R7.htm 00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://lixte.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 7 false false R8.htm 00000008 - Disclosure - Organization and Basis of Presentation Sheet http://lixte.com/role/OrganizationAndBasisOfPresentation Organization and Basis of Presentation Notes 8 false false R9.htm 00000009 - Disclosure - Business Sheet http://lixte.com/role/Business Business Notes 9 false false R10.htm 00000010 - Disclosure - Summary of Significant Accounting Policies Sheet http://lixte.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 10 false false R11.htm 00000011 - Disclosure - Stockholders' Equity Sheet http://lixte.com/role/StockholdersEquity Stockholders' Equity Notes 11 false false R12.htm 00000012 - Disclosure - Related Party Transactions Sheet http://lixte.com/role/RelatedPartyTransactions Related Party Transactions Notes 12 false false R13.htm 00000013 - Disclosure - Stock-Based Compensation Sheet http://lixte.com/role/Stock-basedCompensation Stock-Based Compensation Notes 13 false false R14.htm 00000014 - Disclosure - Commitments and Contingencies Sheet http://lixte.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 14 false false R15.htm 00000015 - Disclosure - Subsequent Events Sheet http://lixte.com/role/SubsequentEvents Subsequent Events Notes 15 false false R16.htm 00000016 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://lixte.com/role/SummaryOfSignificantAccountingPolicies 16 false false R17.htm 00000017 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://lixte.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://lixte.com/role/SummaryOfSignificantAccountingPolicies 17 false false R18.htm 00000018 - Disclosure - Stockholders' Equity (Tables) Sheet http://lixte.com/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://lixte.com/role/StockholdersEquity 18 false false R19.htm 00000019 - Disclosure - Stock-Based Compensation (Tables) Sheet http://lixte.com/role/Stock-basedCompensationTables Stock-Based Compensation (Tables) Tables http://lixte.com/role/Stock-basedCompensation 19 false false R20.htm 00000020 - Disclosure - Business (Details Narrative) Sheet http://lixte.com/role/BusinessDetailsNarrative Business (Details Narrative) Details http://lixte.com/role/Business 20 false false R21.htm 00000021 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) Sheet http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of Significant Accounting Policies (Details Narrative) Details http://lixte.com/role/SummaryOfSignificantAccountingPoliciesTables 21 false false R22.htm 00000022 - Disclosure - Summary of Significant Accounting Policies - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details) Sheet http://lixte.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails Summary of Significant Accounting Policies - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details) Details 22 false false R23.htm 00000023 - Disclosure - Stockholders' Equity (Details Narrative) Sheet http://lixte.com/role/StockholdersEquityDetailsNarrative Stockholders' Equity (Details Narrative) Details http://lixte.com/role/StockholdersEquityTables 23 false false R24.htm 00000024 - Disclosure - Stockholders' Equity - Schedule of Warrants Outstanding (Details) Sheet http://lixte.com/role/StockholdersEquity-ScheduleOfWarrantsOutstandingDetails Stockholders' Equity - Schedule of Warrants Outstanding (Details) Details 24 false false R25.htm 00000025 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://lixte.com/role/RelatedPartyTransactions 25 false false R26.htm 00000026 - Disclosure - Stock-Based Compensation (Details Narrative) Sheet http://lixte.com/role/Stock-basedCompensationDetailsNarrative Stock-Based Compensation (Details Narrative) Details http://lixte.com/role/Stock-basedCompensationTables 26 false false R27.htm 00000027 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity Including Options Form of Warrants (Details) Sheet http://lixte.com/role/Stock-basedCompensation-SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails Stock-Based Compensation - Summary of Stock Option Activity Including Options Form of Warrants (Details) Details 27 false false R28.htm 00000028 - Disclosure - Stock-Based Compensation - Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants (Details) Sheet http://lixte.com/role/Stock-basedCompensation-ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails Stock-Based Compensation - Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants (Details) Details 28 false false R29.htm 00000029 - Disclosure - Commitments and Contingencies (Details Narrative) Sheet http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative Commitments and Contingencies (Details Narrative) Details http://lixte.com/role/CommitmentsAndContingencies 29 false false R30.htm 00000030 - Disclosure - Subsequent Events (Details Narrative) Sheet http://lixte.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://lixte.com/role/SubsequentEvents 30 false false All Reports Book All Reports lixt-20190331.xml lixt-20190331.xsd lixt-20190331_cal.xml lixt-20190331_def.xml lixt-20190331_lab.xml lixt-20190331_pre.xml http://xbrl.sec.gov/currency/2019-01-31 http://fasb.org/us-gaap/2019-01-31 http://xbrl.sec.gov/dei/2018-01-31 http://fasb.org/srt/2019-01-31 true true ZIP 45 0001493152-19-006670-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-19-006670-xbrl.zip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end

Stockholders' Equity - Schedule of Warrants Outstanding (Details) - Common Stock Warrants [Member]	3 Months Ended
	Mar. 31, 2019 $ / shares shares
Number of Shares, Warrants Outstanding, Beginning Balance \| shares	9,000,000
Number of Shares, Issued \| shares
Number of Shares, Exercised \| shares
Number of Shares, Expired \| shares
Number of Shares, Warrants Outstanding, Ending Balance \| shares	9,000,000
Weighted Average Exercise Price, Outstanding, Beginning \| $ / shares	$ 1.000
Weighted Average Exercise Price, Issued \| $ / shares
Weighted Average Exercise Price, Exercised \| $ / shares
Weighted Average Exercise Price, Expired \| $ / shares
Weighted Average Exercise Price, Outstanding, Ending \| $ / shares	$ 1.000
Weighted Average Remaining Contractual Life (in Years), Outstanding	3 years 8 months 2 days